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Vascular oxidative stress is accompanied by an endothelium-dependent 
dysfunction. Reactive oxygen species (ROS) are described as proatherogenic 
stimuli which mediate angiogenesis, inflammation and vascular smooth 
muscle cell (VSMC) proliferation. In addition, inactivation of nitric oxide (NO) 
by superoxide (O2−) and other ROS appears to be a fundamental event 
occuring under conditions such as diabetes mellitus, hypercholesterolemia, 
cigarette smoking or arterial hypertension - common risk factors for 
cardiovascular diseases. Xanthine oxidase (XOD), uncoupled endothelial 
nitric oxide synthase (eNOS) and NADPH oxidases are described as relevant 
origins of oxidative stress in the vasculature. The vascular NADPH oxidase 
complex contains one of three different catalytic subunits termed Nox1, Nox2 
and Nox4, and has been recently suggested as being the major source of 
ROS in blood vessels. Nevertheless, the relative contribution of both the Nox 
isoforms as well as the other above mentioned sources of ROS to oxidative 
stress still remains to be determined. Therefore, keeping this in mind, one  
major aim of the present work was to investigate the activity of XOD, eNOS 
and NADPH oxidases as well as the expression of Nox1, Nox2 and Nox4 in 
the aorta of 12-14 month old spontaneously hypertensive rats (SHR) which 
exhibit increased oxidative stress in comparison to age-matched 
normotensive Wistar Kyoto rats (WKY). Based on the findings evaluated in 
this model and taking into account that the modulation of vascular NADPH 
oxidases promises to have therapeutic potential in the treatment of oxidative 
stress-related vascular diseases, the present study also focussed on the 
investigation of the novel NAPDH oxidase inhibitor VAS2870 (3-Benzyl-7-(2-
benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine) on aortic ROS formation and 
endothelium-dependent relaxation in SHR. 
 
2 
2 SCIENTIFIC BACKGROUND 
 
2.1 Oxidative stress and the biology of reactive oxygen species 
 
Oxygen metabolism, although essential for life, imposes a potential threat to 
cells because of the formation of ROS, such as O2−, hydrogen peroxide 
(H2O2), hydroxyl radicals and a variety of other reaction products (Fridovich, 
1998). ROS can oxidize biological macromolecules such as DNA, proteins, 
lipids and carbohydrates. To avoid this damage, organisms developed 
antioxidant defense systems consisting of ROS catabolizing enzymes and 
antioxidants, such as ascorbate and the tocopherols. Oxidative stress can 
therefore be defined as the pathogenic outcome of an oxidant production that 
overwhelms the endogenous antioxidant defense system. This condition has 
been linked to the origin and progression of chronic degenerative diseases 
(e.g. cancer, diabetes, atherosclerosis as well as neurodegenerative diseases 
like Alzheimer’s and Parkinsons’s disease) (Droge, 2002). Nevertheless, 
when studying oxidative stress, one should keep in mind that ROS are not 
solely harmful and are accidentally generated as a consequence of an aerobic 
lifestyle. Organisms deliberately produce ROS for host defense. Furthermore, 
moderate physiological concentrations of ROS are implicated in signal 
transduction of biological processes including cell growth, apoptosis and cell 
migration (Taniyama & Griendling, 2003). This suggests that normal cellular 
homeostasis is an outcome of a delicate balance between the rate of ROS 
formation and elimination. 
Reduction of oxygen by one electron leads to the formation of O2−, a process 
that is mediated by a variety of enzyme systems such as the mitochondrial 
respiratory chain, cytochrome P450 monoxygenases, lipoxygenases, xanthine 
oxidases and NADPH oxidases. O2− itself exerts effects in biological tissues 
and is also pivotal in generating other ROS. It reacts readily with NO to form 
peroxynitrite (ONOO−), which is a strong oxidant and nitrating agent 
(Ischiropoulos et al., 1992). Under physiological conditions, superoxide 
dismutase (SOD) minimizes this reaction by converting O2− enzymatically into 





defense is illustrated by a study in SOD2-deficient mice, which developed 
cardiomyopathy and neurodegeneration (Melov et al., 2001). However, while 
H2O2, which diffuses through cell membranes (Krotz et al., 2004) is assumed 
to be involved in intracellular signaling pathways, at higher concentrations it is 
found to be toxic (Rhee, 2006) and can react with reduced transition metals to 
form the highly reactive hydroxyl radical. Thus, enzymatic defense against 
H2O2 provided by catalase and glutathione peroxidase which convert H2O2 
into water is crucial. In phagocytes, myeloperoxidase converts H2O2 into the 
very reactive hypochlorous acid (HOCl). Figure 2.1 shows an overview of 





Figure 2.1: Production and clearance of reactive oxygen species. XOD= xanthine 
oxidase, eNOS = endothelial nitric oxide synthse, SOD = superoxide dismutase, CAT = 







2.2 Effects of ROS in the vasculature 
 
Virtually all types of vascular cells produce O2− and H2O2. ROS have distinct 
functional effects on each vascular cell type and can play both physiological 
and pathophysiological roles. In endothelial cells, ROS have been shown to 
induce signaling processes like apoptosis, expression of adhesion molecules 
and angiogenesis (Taniyama & Griendling, 2003). In smooth muscle cells and 
fibroblasts, promotion of proliferation and migration are mediated by ROS 
(Rey & Pagano, 2002). All these processes are fundamental in the 
homeostasis of the vasculature, but oxidative stress followed by an 
overstimulation of the pathways leads to events such as inflammation, 
hypertrophy, remodeling and angiogenesis, which are hallmarks of many 
cardiovascular diseases. 
Moreover, increased production and release of ROS is considered to be the 
key event in the pathogenesis of endothelial dysfunction. The endothelium-
derived relaxing factor (EDRF) NO plays an essential vasoprotective role by 
dilating blood vessels, preventing thrombus formation, reducing endothelial 
cell permeability and, in the long run, reducing vascular smooth muscle cell 
proliferation (Schmidt & Walter, 1994). The term endothelial dysfunction has 
been used to refer to several pathological conditions which are caused by a 
decline in the bioavailability of NO (Kojda & Harrison, 1999). This 
pathophysiological state is characterized by the impairment of the protective 
functions of NO leading to a loss of vasodilation, platelet aggregation, 
inflammation, smooth muscle cell growth and remodeling (Cai & Harrison, 
2000). A loss of the NO bioavailability may be caused either by a decreased 
expression of eNOS (Wilcox et al., 1997), a lack of substrate or cofactors for 
eNOS (Pou et al., 1992) or accelerated NO scavenging by ROS (Harrison, 
1997). Gryglewski et al. (Gryglewski et al., 1986) discovered that O2− 
inactivates and SOD stabilizes EDRF, even before it was known to be NO. 
The second order rate constant of the reaction between O2− and NO was 
found to be 6.7x109 M−1•s−1 (Thomson et al., 1995) which is three times faster 
than the reaction of O2− with SOD (2.9x109 M−1•s−1) and nearly thirty times 





rapid reaction rate, there is probably some O2− reacting with NO at any given 
time within the cells suggesting a tenuous balance between these molecules 
which is disturbed under pathological conditions (Cai & Harrison, 2000). Apart 
from superoxide, lipid radicals can also react with NO (O'Donnell & Freeman, 
2001), and a recent study reported that hydroxyl radicals may react with NO, 
too (Pieper et al., 1997).  
 
 
2.3 Sources of ROS in the vasculature 
 
The potential enzymatic sources of ROS in the vasculature include 
mitochondrial respiration, lipoxygenases, cyclooxygenases, heme 
oxygenases, cytochrome P450 monoxygenases, peroxidases, NO synthases, 
xanthine oxidases and NADPH oxidases. However, considerable attention 
particularly with regard to oxidative stress was paid to XOD, endothelial NOS 
and NADPH oxidases (Cai & Harrison, 2000; Jiang et al., 2004).  
 
2.3.1 Xanthine oxidase 
 
Xanthine oxidoreductase is generally recognized as the terminal enzyme of 
purine catabolism in humans. This molybdoflavoenzyme, which catalyzes the 
oxidation of hypoxanthine and xanthine, exists in two interconvertible forms, 
xanthine dehydrogenase (XDH) and XOD (for a review, see Harrison (2002)). 
XOD is formed by reversible thiol oxidation or irreversible proteolytic cleavage 
of XDH which predominates in vivo (XDH: approx. 80%, XOD: approx. 20%) 
(Parks et al., 1988; Frederiks & Bosch, 1996). While XDH preferentially 
reduces NAD+, XOD is not able to reduce NAD+ but prefers molecular oxygen 
as its substrate leading to the generation of O2− and H2O2 (Cai & Harrison, 
2000). A pathological role of XOD-derived ROS was first proposed by 
Granger and colleagues suggesting XOD as the key enzyme responsible for 
oxidative stress following ischemia reperfusion injury (Granger et al., 1981; 
McCord, 1985). Furthermore, several studies have thereafter reported the 





under conditions such as hypertension (Nakazono et al., 1991; Miyamoto et 
al., 1996) and hypercholesterolemia (White et al., 1996; Cardillo et al., 1997). 
Most studies investigating the role of XOD in oxidative stress are based upon 
oxypurinol as well as allopurinol, which inhibit xanthine oxidoreductase by 
targeting the molybdenum site of the enzyme. However, studies using high 
concentrations of these inhibitors should be interpreted with caution, because 
allopurinol and oxypurinol have been described to possess free radical-
scavenging properties in concentrations higher than 500 µM (Moorhouse et 
al., 1987). Due to the unavailability of a specific antibody for XOD (Cai & 
Harrison, 2000), its role in vascular oxidative stress is superficial and awaits 
further clarification. 
 
2.3.2 Endothelial NO synthase 
 
Endogenous NO is produced by NOS. There are three different NOS 
isoforms, namely endothelial NOS (eNOS, NOSIII), which is the predominant 
isoform in the vasculature, inducible NOS (iNOS, NOSII) and neuronal NOS 
(nNOS, NOSI). All NOS homologues form homodimers in which the two 
monomers are linked by a single zinc thiolate cluster. The monomer contains 
two functionally different domains: An N-terminal oxygenase where heme, 
tetrahydrobiopterin (BH4) and L-arginine bind and a C-terminal reductase 
comprising binding sites for FMN, FAD and NADPH. Both domains are linked 
by a calmodulin binding site. Ca2+-induced calmodulin binding enables 
electron transfer from NADPH via the flavins to the heme centre for oxidation 
of the substrate L-arginine. Binding of BH4 close to the heme group is required 
for the transfer of the electrons to the guanidine nitrogen of L-arginine to form 
NO and L-citrulline (for a review, see Alderton et al. (2001); Bruckdorfer 
(2005)). Under certain conditions NOS becomes uncoupled and produces O2− 
and H2O2 instead of NO (Pou et al., 1992). This can occur, if concentrations of 
either L-arginine or the essential co-factor BH4 are low or if the zinc thiolate 
complex is disrupted (for a review, see Förstermann (2006)). Oxidative stress 
is suggested to lead to eNOS uncoupling (Laursen et al., 2001; Landmesser 





oxidative stress is founded by the observations that administration of BH4 
restores endothelial dysfunction (Cosentino & Luscher, 1998) and that 
peroxynitrite is able to oxidize BH4 (Milstien & Katusic, 1999). Recently, Zou 
and colleagues (2002) have pointed out an alternative concept by showing 
that much lower levels of peroxynitrite than necessary for BH4 oxidation lead 
to a disruption of the zinc thiolate cluster of the enzyme. Nevertheless, these 
studies suggest that uncoupled eNOS is relevant in amplifying ROS 
generation. Inhibition of NOS in its functional as well as 
unfunctional/uncoupled state can be achieved by using the L-arginine 
analogue L-NAME. 
 
2.3.3 NADPH oxidases 
 
NADPH oxidases are thought to be the predominant source of ROS in the 
vasculature (Griendling et al., 2000). Intriguingly, NADPH oxidases appear to 
be the only dedicated ROS forming enzymes, whereas ROS generation by 
XOD, eNOS or mitochondria appears to occur accidentally. The sole purpose 
of NADPH oxidases is the formation of ROS and that favours these enzymes 
as outstanding targets for the treatment of oxidative stress. Therefore, their 
structure, activation and pharmacology will be discussed in more detail in 
chapter 2.4. 
 
2.3.4 The “kindling bonfire” hypothesis 
 
Many studies support a critical role of the above-mentioned enzymes in the 
pathology of vascular diseases. Their individual contribution to oxidative 
stress appears to be dependent on the cellular and subcellular circumstances 
as well as the environment (e.g. eNOS uncoupling occurs if BH4 levels are 
low) (Jiang et al., 2004). An interesting hypothesis is that NADPH oxidases 
initiate oxidative stress at early stages of vascular diseases and then trigger 
themselves (Li et al., 2001) as well as other ROS sources leading to 
progressed oxidative stress and endothelial dysfunction (Landmesser et al., 





be in a substantial interplay with each other leading to feed forward processes 
and augmented ROS generation (Mueller et al., 2005). The relative 
contribution of these sources of ROS to oxidative stress therefore seems to 
be dependent on the disease state and remains to be defined in the 
pathogenesis of vascular diseases. Figure 2.2 shows an overview of the 




Figure 2.2: Oxidative stress and endothelial dysfunction in cardiovascular diseases.  









NADPH oxidases are a group of membrane-associated enzymes that are 
expressed in various cells of mesodermal origin. The structure and function of 
NADPH oxidases are well characterized in phagocytic cells (neutrophils, 
macrophages and eosinophils) where these multimeric protein complexes 
produce large amounts of O2− (termed as oxidative or respiratory burst) for 
host defense (for a review, see Babior (1999); Vignais (2002); Groemping & 
Rittinger (2005)). NADPH oxidases generate O2− by catalyzing the one 
electron reduction of oxygen according to the following equation: 
 
NADPH + 2 O2   2 O2− + NADP+ + H+ 
 
The leucocyte NADPH oxidase consists of two membrane components, a 
small α-subunit, p22phox, and a larger catalytic β-subunit, gp91phox (termed 
Nox2 according to the new nomenclature and, will therefore be referred to as 
Nox2 in the following chapters). Nox2 is a highly glycosylated protein that has 
a molecular weight of 65.3 kD, but runs as a broad smear around 91 kD on 
SDS-PAGE gels. It possesses six transmembrane α-helices and contains 
binding sites for NADPH, molecular oxygen as well as flavin and heme groups 
to allow electron transport from NADPH to O2. The small subunit p22phox 
associates with Nox2 in a 1:1 complex and contributes to its maturation and 
stabilization. These two components comprise the cytochrome b558 complex 
(heme absorbance peak at 558 nm in the reduced state). Furthermore, the 
complex contains four cytoplasmic subunits: p47phox, p67phox, p40phox and the 
guanine nucleotide-binding protein Rac1 or 2, which upon stimulation 
translocates to cytochrome b558. This assembly is required for activation of the 







Figure 2.3: Assembly of the phagocytic NADPH oxidase (modified after Jiang et al. 
(2004)) 
 
Recently, homologues of the catalytic subunit Nox2 have been discovered. 
Starting with Nox1 (Suh et al., 1999) this new enzyme family has to date 
seven members, which are structured into three groups according to the 
presence of specific domains (Lambeth, 2002). The first group includes Nox1, 
primarily expressed in colon epithelial cells (Suh et al., 1999), Nox2, the 
isoform of the leucocytic oxidase, Nox3, found in the inner ear and required 
for otoconia formation (Paffenholz et al., 2004) and finally Nox4, first 
described as Renox due to its prominant expression in the kidney (Geiszt et 
al., 2000). In contrast to this group of Nox2 homologues, which are calcium-
independent, Nox5 contains EF-hand calcium binding motifs and is activated 
by increased calcium levels. This isoform is essentially found in lymphoid 
tissues and testis (Banfi et al., 2001). The third group of homologues – Duox1 
and 2 - further extends the Nox5 structure by a peroxidase homology domain 
(De Deken et al., 2000). Both enzymes are expressed in the thyroid gland and 





Transmembrane topologies and domain structures for the Nox family are 




Figure 2.4: Transmembrane topology and domain structure of Nox family members. All 
homologues are predicted to form six transmembrane domains. This region also contains five 
conserved histidine residues providing binding sites for two heme goups. The carboxy-
terminal part of the molecule contains a FAD as well as a NADPH binding domain. Nox5 and 
the Duox group have a cytosolic calcium binding EF hand. In addition, the Duox enzymes 
possess a further transmembrane domain followed by an extracellularly located peroxidase 
domain, which can use ROS produced by the catalytic core domains to oxidize extracellular 
substrates (R). (modified after Lambeth (2004)) 
 
 
Homologues of two cytosolic subunits have also been discovered: NoxO1 (O 
for organizer) is a homologue of p47phox, and NoxA1 (A for activator) shares 
considerable similarity with p67phox. Both subunits were recently cloned from 
colon epithelial cells and seem to be required for Nox1 activity (Banfi et al., 
2003). Activation of Nox2 and Nox3 by the new cytosolic homologues has 








2.4.2 Expression of subunits in the vasculature 
 
Vascular NADPH oxidases contain Nox1, Nox2 or Nox4 as catalytic subunit. 
In humans, Nox5 has also been found in vessels (Lassegue & Clempus, 
2003), but this isoform is not present in the vasculature of rodents (Maru et 
al., 2005; Gavazzi et al., 2006). The expression profile of these Nox 
homologues varies in the vascular layers. Nox1 is expressed in low amounts 
in VSMC where its activity and expression can be stimulated by mitogenic 
substances such as angiotensin II and platelet-derived growth factor (PDGF) 
(Lassegue et al., 2001). Nox2 is present in endothelial cells (EC) (Meyer et 
al., 1999) and fibroblasts (Rey & Pagano, 2002) and seems to be expressed 
in VSMC of resistance arteries but not conduit vessels (Lassegue et al., 2001; 
Kalinina et al., 2002). In contrast to the relatively low levels of Nox1 and Nox2, 
Nox4 is abundantly expressed in all vascular cells (Sorescu et al., 2002; Ago 
et al., 2004; Brandes & Kreuzer, 2005). The small subunit p22phox is 
expressed in all layers of the vascular wall (Brandes & Kreuzer, 2005). Since 
it has been shown that this subunit stabilizes the Nox isoforms (Ambasta et 
al., 2004) and is important for the function of Nox1-4-based NADPH oxidases 
(Kawahara et al., 2005), such an abundant expression of p22phox is 
expected. 
The cytosolic component p47phox has been detected in all vascular layers of 
conduit as well as resistance vessels and in vascular cell cultures, too 
(Lassegue & Clempus, 2003). In contrast, p67phox has only been found in the 
endothelium and adventitia (Jones et al., 1996; Pagano et al., 1998), but not 
in aortic smooth muscle cells (Patterson et al., 1999). Interestingly, p67phox 
similar to Nox2 has also been detected in VSMC of human resistance arteries 
(Touyz et al., 2002). The precise role of the new homologues NoxO1 and 
NoxA1 in the vasculature still remains to be determined. Recently, the 
expression of NoxA1 has been shown in VSMC of mouse carotid artery 
indicating that it replaces p67phox in the media of large vessels (Brandes & 
Kreuzer, 2005; Ambasta et al., 2006). Finally, Rac1 has been shown to be 






2.4.3 Activation of the phagocytic NADPH oxidase 
 
The process of NADPH oxidase activation has been well characterized in 
leucocytes. In the resting state, the subunits p47phox, p67phox and p40phox are 
located in the cytosol and interact with each other in a trimeric (1:1:1) complex 
(Vignais, 2002). During this stage, p47phox is in an auto-inhibited conformation 
where two SH3 domains bind via an intramolecular interaction to a polybasic 
region (Groemping et al., 2003). Upon activation, p47phox becomes highly 
phosphorylated. This is required to abolish the auto-inhibition and allows its 
translocation to cytochrome b558 (Ago et al., 2003). Thereby p47phox organizes 
the assembly of the (p47-p67-p40phox) triade to the membrane and docks via 
its SH3 domains to p22phox (Groemping et al., 2003). In addition, three 
interaction sites are reported between p47phox and Nox2 (DeLeo et al., 1995). 
The docking of p47phox to cytochrome b558 also facilitates the interaction 
between p67phox and Nox2 which is required for the activation of the catalytic 
subunit (Han et al., 1998). Another critical step in the activation process is the 
translocation of the activated GTPase Rac to cytochrome b558. This binding is 
independent of p47phox since Rac-GTP anchors itself in the membrane via its 
prenylated tail (Brandes & Kreuzer, 2005). Finally, previous findings suggest 
that the presence of free fatty acids is required for the formation of the 
complex, at least under in vivo conditions (Dana et al., 1998). 
Various stimulators can be used to target the phagocytic NADPH oxidase. 
Phorbol-myristate-acetate (PMA) activates protein kinase C (PKC), which 
phosphorylates p47phox and thereby induces a strong long-lasting oxidative 
burst. Other agonists of the phagocytic NADPH oxidase are opsonized 
zymosan and the chemoattractant formyl-methionyl-leucyl-phenylalanine. All 
these substances finally lead to the phosphorylation of p47phox, activation of 
Rac and release of free fatty acids - the molecular triggers for the NADPH 








2.4.4 Activation of vascular NADPH oxidases  
 
The exact composition and assembly of vascular NADPH oxidases is poorly 
understood. While it is assumed that vascular Nox2 based oxidases follow a 
similar assembly mechanism as demonstrated for phagocytes, it has been 
shown that Nox1 activation requires NoxO1 and NoxA1. In contrast, Nox4 
activity appears to be independent of the known cytosolic subunits.  
In contrast to phagocytic cells, vascular cells exhibit a constitutively active 
oxidase which generates low amounts of ROS; the rate of O2− is thought to be 
1-10% of that in leucocytes (Lassegue & Clempus, 2003). In line with this, a 
preassembled oxidase was found in endothelial cells, consisting of Nox2, 
p22phox, p47phox and p67phox (Li & Shah, 2002). A constitutive activity is also 
suggested for Nox4 which was shown to produce ROS if coexpressed with 
p22phox, however the cytosolic subunits p47phox and p67phox as well as the 
novel subunits NoxO1 and NoxA1 did not further increase its activity (Ago et 
al., 2004; Ambasta et al., 2004; Kawahara et al., 2005). NoxO1 and NoxA1 
have not been investigated in vascular tissue so far. However, the lack of the 
autoinhibitory loop in NoxO1 in comparison to its homologue p47phox and the 
fact that it is prelocated at the membrane suggests an increased basal activity 
of NoxO1-based NADPH oxidases (Cheng & Lambeth, 2004). 
NADPH oxidases in vascular cells can be activated by a number of stimuli 
such as angiotensin II, thrombin, PDGF, tumor necrosis factor-α (TNF-α), 
interleukin-1, vascular endothelial growth factor (VEGF) or mechanical forces 
like shear stress, although the resulting amounts of ROS are only a fraction of 
the phagocytic ROS generation (Stocker & Keaney, 2004). A key role for 
p47phox in mediating angiotensin II-induced NADPH oxidase activation has 
been demonstrated by use of p47phox-/- mice. Isolated EC and VSMC of these 
knockout mice did not produce O2−. in response to angiotensin II (Lavigne et 
al., 2001; Landmesser et al., 2002; Li & Shah, 2003).  Furthermore, 
angiotensin II and PDGF upregulate Nox1 expression in rat VSMC, whereas 
transfection of these cells with antisense Nox1 mRNA inhibited superoxide 
production in response to these stimuli, but had no effect on basal ROS 





indicates that Nox1 is essential for agonist-stimulated NADPH oxidase activity 
in VSMC. Nox2 has also been suggested to be responsive to agonists that 
promote ROS formation, since stimuli such as TNF-α, PMA or angiotensin II 
fail to generate ROS in EC and adventitial fibroblasts from Nox2-/- mice 
(Gorlach et al., 2000; Frey et al., 2002; Rey et al., 2002). 
The constitutive and rather low activity of vascular NADPH oxidases suggests 
that they could play a role in signal transduction processes. The observation 
that ROS generation occurs mainly intracellularly provides another hint for 
their role in mediating signal transduction. However, under pathophysiological 
conditions, NADPH oxidases appear to be significantly involved in the 
oxidative stress found in a variety of cardiovascular diseases. 
 
2.4.5 Pharmacology of NADPH oxidases 
 
A number of inhibitors of NADPH oxidases have been used in experimental 
research. However, all of the currently available inhibitors have their 
drawbacks. They can be differentiated into peptide- and non-peptide-based 
inhibitors. Among the former, the antibiotic peptide PR-39 blocks leucocytic 
NADPH oxidase activity by binding p47phox and preventing its translocation to 
cytochrome b558 (Shi et al., 1996). This proline-arginine (PR) rich peptide, 
which is endogenously secreted by human and/or porcine intestine and 
neutrophils, interacts with SH3 domains of p47phox (Shi et al., 1996). PR-39 
also inhibits non-phagocytic NADPH oxidases as observed in porcine 
pulmonary artery EC (Al-Mehdi et al., 1998) and decreases ROS production in 
ischemic reperfusion models of rat lungs (Al-Mehdi et al., 1998) and hearts 
(Ikeda et al., 2001). However, recent studies reveal non-specific effects of PR-
39, because it binds to the SH3 domains of other proteins and interacts with 
membrane lipids (Chan et al., 2001; Tanaka et al., 2001). Rey et al. (2001) 
have developed a chimeric oligopeptide (“gp91-ds-tat”) consisting of 9 amino 
acids of Nox2 (formerly gp91phox) known to interact with p47phox (docking 
sequence ds) and to inhibit NADPH oxidase activity (DeLeo et al., 1995). This 
peptide was attached to a 9-aa sequence derived from the HIV-coat protein 





ds-tat competitively binds p47phox and thus prevents the assembly of NADPH 
oxidases (Rey et al., 2001). Multiple studies have been carried out with gp91-
ds-tat in a variety of models, e.g. showing its in vivo effectiveness by inhibition 
of angiotensin II-induced hypertension (Rey et al., 2001) or neointima 
proliferation following balloon injury (Jacobson et al., 2003). Whether gp91-ds-
tat is solely specific for Nox2 (Cai et al., 2003; Cifuentes & Pagano, 2006) or 
inhibits all vascular subunits (Brandes, 2003), is still a matter of debate and 
needs further clarifying studies. However, the tat portion alone appears to 
have effects, recommending control experiments using a peptide with a 
scrambled gp91 docking sequence.  
Several non-peptide compounds have been used to inhibit NADPH oxidases; 
however, most of these are of dubious specificity. For example, Nox-catalyzed 
ROS production has traditionally been inhibited by the flavin antagonist 
diphenylene iodonium (DPI). This substance effectively inhibits all 
flavoenzymes (Majander et al., 1994), including NOS and cytochrome P450 
and therefore little information on the specific role of NADPH oxidases is 
gained by using DPI, except exclusion of a role of all flavoenzymes in ROS 
production. Phenylarsine oxide (PAO) also directly targets the catalytic 
subunit Nox2 by forming ring complexes with vicinal or neighbouring thiols 
(Vignais, 2002). A similar mode of action is suggested to be partly responsible 
for the inhibition of NADPH oxidase by gliotoxin, a toxin derived from 
Aspergillus spp. and Candida spp. (Nishida et al., 2005). In addition, it has 
been shown that gliotoxin impedes the colocalization of PKC-β2 with p47phox 
and thereby prevents the essential phosphorylation of this organizing subunit 
(Tsunawaki et al., 2004). 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) 
is able to block the p47phox organized assembly of the NADPH oxidase 
complex, but at the same time is also an irreversible serine protease inhibitor 
(Diatchuk et al., 1997). Other compounds that have been suggested to inhibit 
NADPH oxidases are neopterin (Kojima et al., 1993) and plumbagin (Ding et 
al., 2005); the mechanisms of action of both compounds are poorly 
understood. Recently, a novel flavonoid derivative, S17834, has been shown 
to inhibit TNF-stimulated NADPH oxidase activity in EC (Cayatte et al., 2001). 





al., 2001). However, its mechanism of action is also unknown and no other 
information about S17834 is currently available in the literature. Among all 
NADPH oxidase inhibitors the one of most frequently used is apocynin (4-
hydroxy-3-methoxy-acetophenone). This natural compound, which was 
isolated from the roots of Picrorhiza kurroa, a plant used in Ayurvedic 
medicine for the treatment of asthma (Basu et al., 1971), inhibits NADPH 
oxidase activity in neutrophils (Simons et al., 1990) as well as non-phagocytic 
cells (Meyer et al., 1999). The proposed mechanism of action of apocynin is 
that it prevents the translocation of p47phox and p67phox to the membrane 
(Stolk et al., 1994; Meyer et al., 1999). It is suggested, that apocynin requires 
the presence of H2O2 and peroxidases to be converted into an active 
metabolite which was characterized as a 5’-5’-dimer called diapocynin (Stolk 
et al., 1994; Johnson et al., 2002; Vejrazka et al., 2005). Due to its high oral 
bioavailability, low toxicity and efficacy in vivo the compound seems to have a 
promising potential even for clinical therapeutics; for example, apocynin was 
able to prevent hypertension in rats (Beswick et al., 2001) and mice (Virdis et 
al., 2004). However, recent studies show that apocynin can even stimulate 
ROS production in non-phagocytic cells thereby questioning the specificity of 
this substance (Riganti et al., 2005; Vejrazka et al., 2005). Moreover, 
apocynin has to be applied in relatively high concentrations (< 500 µM) and it 
seems that the effect of apocynin varies depending on the inherent 
peroxidase activity of cells and tissues (Cifuentes & Pagano, 2006).  
An overview of the mechanisms of action of NADPH oxidase inhibitors is 
shown in Figure 2.5. In conclusion, the pharmacology of NADPH oxidases is 
poorly developed. Most inhibitors appear to be either non-specific or their 
mechanism of action is unclear. In the quest for new compounds with high 
potency and specificity, a high-throughput screening was performed with PMA 
stimulated human leucocytes (DMSO differentiated HL60 cells) (Tegtmeier F 
et al., 2005). In this oxidative burst assay, a compound with a 1,2,3-
triazolo[4,5-d]pyrimidine structure, namely VAS2870, was found to be highly 
effective. Flavoenzyme inhibition and antioxidative effects could be excluded 
by means of a xanthine/xanthine oxidase assay (Ten Freyhaus et al., 2006). 





as well as in vivo remain to be elucidated. The structures of the above 




Figure 2.5: Mechanism of action of NADPH oxidase inhibitors. Modified scheme after 
Brandes (2003). For details, see text. 
 
Figure 2.6: Structures of NADPH oxidase inhibitors. A. PR39. B. gp91phox-ds-tat peptide. 
C. DPI. D. AEBSF. E. PAO. F. Gliotoxin. G. Neopterine. H. Plumbagin. I. S17834. J. 





2.5 ROS and vascular diseases 
 
Animal as well as human studies support a fundamental role of ROS in 
cardiovascular diseases. In animal models of atherosclerosis, lesion formation 
is associated with an accumulation of lipid peroxidation products and an 
inactivation of NO resulting in endothelial dysfunction (for a review, see 
Griendling & FitzGerald (2003)). In rabbits fed with cholesterol, superoxide 
was increased in the aorta resulting in an impaired endothelial-dependent 
relaxation which could be reversed by treatment with PEG-SOD (Mugge et al., 
1991). XOD seems to be involved in superoxide production associated with 
hypercholesterolemia, since oxypurinol normalized the increased ROS 
generation (Ohara et al., 1993) and improved the impaired vasodilation in 
hypercholesterolemic patients (Cardillo et al., 1997). A significant role of 
NADPH oxidases was demonstrated in apolipoprotein E and p47phox double-
knockout mice (ApoE-/-/p47phox-/-) where a marked reduction of lesions was 
observed in the descending aorta (Barry-Lane et al., 2001). In human 
atherosclerotic arteries, Nox2 expression, mainly associated with intimal 
macrophages, showed a strong correlation with lesion severity, whereas Nox4 
mRNA remained unchanged throughout most stages of atherosclerosis; 
however, the expression level of Nox4 was much lower in most advanced 
atherosclerotic lesions (Sorescu et al., 2002). Diabetes mellitus (DM) is 
another disorder associated with increased vascular ROS production. The 
resulting endothelial dysfuntion was demonstrated in streptozotocin-treated 
rats (a model of type-I-DM), in genetically diabetic rats (a model of type-II-DM) 
and human patients with type-II-DM (Griendling & FitzGerald, 2003). 
Pretreatment of the diabetic rat aorta with SOD significantly improved the 
endothelium-dependent relaxation (Langenstroer & Pieper, 1992), and 
NADPH oxidases as well as uncoupled eNOS have been identified as major 
sources of oxidative stress (Guzik et al., 2002). Other cardiovascular diseases 
including cardiac hypertrophy, heart failure, nitrate tolerance and restenosis 
after angioplasty are also accompanied by oxidative stress and increased 





Vascular oxidative stress has been described in experimental hypertension 
such as angiotensin II-induced hypertension, Dahl salt-sensitive hypertension, 
DOCA-salt hypertension, or aldosterone-provoked hypertension (Touyz, 
2004). NADPH oxidase, XOD and uncoupled eNOS have been identified as 
sources of amplified ROS generation in these models (Touyz, 2004). For 
example, several studies suggest a fundamental role of NADPH oxidase in 
angiotensin II-mediated oxidative stress and hypertension. Chronic infusion of 
angiotensin II in rats increased blood pressure and NADPH oxidase-derived 
O2− production which could be prevented by pretreating the animals with the 
AT1 receptor antagonist losartan (Rajagopalan et al., 1996). Concomitant with 
the increased NADPH oxidase activity, p22phox mRNA as well as p67phox and 
Nox2 protein levels were also elevated (Fukui et al., 1997; Cifuentes et al., 
2000). Furthermore, p47phox-deficient mice showed a markedly decreased 
pressure response and no increase in O2− generation after angiotensin II 
infusion in comparison to wildtype mice (Landmesser et al., 2002). 
Genetic hypertension is also accompanied with pathophysiological levels of 
ROS. Spontaneously hypertensive rats (SHR) exhibit increased O2− 
production in venules as well as arterioles and heparin-binding SOD is able to 
normalize the blood pressure of these hypertensive animals (Nakazono et al., 
1991; Suzuki et al., 1995). Zalba et al. (2000) have reported that enhanced 
NADPH oxidase activity is associated with endothelial dysfunction and 
vascular hypertrophy in the aorta of 30 week old SHR, whereas these 
parameters were unchanged in young SHR (16 weeks old) in comparison to 
their age-matched normotensive WKY controls. Additionaly, an age-
dependent increase in NADPH oxidase activity and decreased NO 
bioavailability has been reported in a study using aorta from 3-4 and 9-12 
month old stroke-prone SHR (Hamilton et al., 2001). Furthermore, increased 
NADPH oxidase activity in SHR is accompanied by an upregulation of p22phox 
mRNA and protein expression which has been suggested to be a 
consequence of an overactivity of the renin-angiotensin system as well as 
polymorphisms in the p22phox gene promoter (Hamilton et al., 2001; Zalba et 
al., 2001). However, the involvement of the individual vascular Nox 





described as a critical source of vascular superoxide generation in stroke-
prone SHR (Kerr et al., 1999). Treatment with either antioxidant vitamins, 
SOD mimetics, apocynin, BH4 or AT1 receptor blockers suppresses the 
vascular ROS generation and attenuates the development of hypertension in 
these models (Hamilton et al., 2002; Park et al., 2002; Rodriguez-Iturbe et al., 
2003; Fortepiani & Reckelhoff, 2005). In summary, these data indicate that 
NADPH oxidases and a dysfunctional eNOS are involved in the generation of 
oxidative stress observed in genetic hypertension. 
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3 AIMS OF THE STUDY 
 
The present study was carried out to identify the contribution of NADPH 
oxidases to vascular oxidative stress and endothelial dysfunction in essential 
hypertension using aortae of 12-14 month old male SHR and their respective 
WKY controls. Based on the achieved findings, the effectiveness of the novel 
NADPH oxidase inhibitor VAS2870 should be tested. The following 
experimental approaches were thus applied: 
 
i. Investigating the enzymatic sources of ROS in aortae of SHR. XOD, 
uncoupled eNOS and especially vascular NADPH oxidases are suggested to 
promote oxidative stress in many cardiovascular diseases. Therefore, 
increased ROS production in SHR aorta in comparison to WKY should be 
investigated and the contribution of the individual ROS generating enzymes 
determined by using specific enzyme inhibitors. 
ii. Investigating the contribution of vascular Nox isoforms to NADPH 
oxidase activity. The involvement of the vascular Nox homologues in 
increased NADPH oxidase activity of SHR has not yet been clarified. For this 
reason, protein expression of Nox1, Nox2 and Nox4 should be determined in 
SHR and WKY aortae. 
iii. Investigating the localization of Nox isoforms within the aortic wall of 
SHR and WKY. The distribution of the Nox homologues in the aortic wall is 
poorly investigated at the protein level. Thus, possible differences of the Nox 
distribution between SHR and WKY aorta should be examined using 
immunohistochemistry. 
iv. Investigating the effect of NADPH oxidase inhibition on endothelial 
function in SHR aorta. Oxidative stress decreases NO bioavailability thereby 
leading to impaired endothelium-dependent relaxation, a measure for 
endothelial function. Thus, the hypothesis that inhibition of NADPH oxidases 
by the novel inhibitor VAS2870 leads to improved endothelium-dependent 









β-Mercaptoethanol Carl Roth GmbH (Karlsruhe) 
100 kb smart ladder (Marker/DNA) Eurogentec (Seraing, Belgium) 
Acetylcholine Sigma (Deisenhofen) 
Acrylamide (30%) with  
Bisacrylamide (0.8%) 
Carl Roth GmbH (Karlsruhe) 
Agaraose Carl Roth GmbH (Karlsruhe) 
Alcian blue 8GS Carl Roth GmbH (Karlsruhe) 
Ampicillin Carl Roth GmbH (Karlsruhe) 
Apocynin Calbiochem (Darmstadt) 
APS Merck (Darmstadt) 
Azophloxin Fluka (Taufkirchen) 
Bromphenol blue Sigma (Deisenhofen) 
BSA Sigma (Deisenhofen) 
CaCl2 Merck (Darmstadt) 
Casein-hydrolysate Sigma (Deisenhofen) 
Complete EDTA-free protease-
inhibitor cocktail 
Roche Molecular Biochemicals 
(Mannheim) 
CuSO4⋅5H2O Merck (Darmstadt) 
DHE Molecular Probes (Eugene, USA) 
DMSO Carl Roth GmbH (Karlsruhe) 
dNTPs PeqLab Biotechnologie (Erlangen) 
DPI Sigma (Deisenhofen) 
EDTA Sigma (Deisenhofen) 
Ethidium bromide Carl Roth GmbH (Karlsruhe) 
FeCl3 Fluka (Taufkirchen) 
Folin-Chiocalteu`s phenol agent Merck (Darmstadt) 
Glacial acetic acid Merck (Darmstadt) 




Glucose Carl Roth GmbH (Karlsruhe) 
Glycine Carl Roth GmbH (Karlsruhe) 
HBSS PAA Laboratories (Pasching, Austria) 
Hematoxylin Merck (Darmstadt) 
HEPES Sigma (Deisenhofen) 
Hoechst dye 33342 Molecular Probes (Eugene, USA) 
IPTG Carl Roth GmbH (Karlsruhe) 
KCl Carl Roth GmbH (Karlsruhe) 
KH2PO4 Carl Roth GmbH (Karlsruhe) 
Light green Chroma (Köngen) 
L-NAME Sigma (Deisenhofen) 
Lucigenin Sigma (Deisenhofen) 
Methanol Merck (Darmstadt) 
MgCl2 Carl Roth GmbH (Karlsruhe) 
MgSO4ּ7H2O Merck (Darmstadt) 
NaCl Merck (Darmstadt) 
NADPH (reduced) AppliChem (Darmstadt) 
NaHCO3 Merck (Darmstadt) 
NaOH Carl Roth GmbH (Karlsruhe) 
Normal goat serum DAKO (Hamburg) 
Nuclear fast red Merck (Darmstadt) 
Orange G Chroma (Köngen) 
Orcein Chroma (Köngen) 
Oxypurinol Sigma (Deisenhofen) 
PEG-SOD Sigma (Deisenhofen) 
Phenylephrine hydrochloride Sigma (Deisenhofen) 
Phosphortungstic acid Merck (Darmstadt) 
Picric acid Carl Roth GmbH (Karlsruhe) 
Picroindigocarmin Chroma (Köngen) 
PNGase F from Flavobacterium 
meningosepticum 
Roche Molecular Biochemicals 
(Mannheim) 
Pure H2O (RNase/DNase free) Fluka (Taufkirchen) 




Random Hexamer Primer Invitrogen (Karlsruhe) 
RNase away Molecular Bioproducts (San Diego, USA) 
Rotihistokit® Carl Roth GmbH (Karlsruhe) 
Rotihistol® Carl Roth GmbH (Karlsruhe) 
SDS Carl Roth GmbH (Karlsruhe) 
SOD from bovine erythrocytes Sigma (Deisenhofen) 
Sodium tartrate Merck (Darmstadt) 
TEMED Sigma (Deisenhofen) 
Tiron Sigma (Deisenhofen) 
Tissue Tek OCT Compound Sakura Finetek (Torrance, USA) 
Tris Carl Roth GmbH (Karlsruhe) 
VAS 2870 Vasopharm BIOTECH GmbH (Würzburg) 
X-Gal Carl Roth GmbH (Karlsruhe) 
Yeast extract Carl Roth GmbH (Karlsruhe) 
 




Apparatus Type Producer 
Analytical balance AT 250 E. Mettler (Zürich, 
Switzerland) 
Analytical balance M5 E. Mettler (Zürich, 
Switzerland) 
Camera system EDAs 290  Kodak (New Haven, USA) 
Centrifuge 5804 Eppendorf (Hamburg) 





Thermo labsystems (Vantaa, 
Finland) 
CO2 incubator BB 6220 Heraeus instruments (Hanau) 
Computer iMac Power PC G4 Apple (Cupertino, USA) 
Copy machine DiAlta di 351 (Minolta, Hannover) 




Cryostat CM 1900 Leica Microsystems 
(Nussloch) 
Electrophoresis 
chamber for agarose 
gels 




DM 6000 B Leica (Wetzlar) 
Image station Kodak 440 CF Rochester (NY, USA) 
Isolated organ 
apparatus  
IOA 5306 FMI Föhr Medical Instruments 
(Seeheim/Ober-Beerbach) 
Microscope CKX 41 Olympus (Hamburg) 
Microwave  Sharp (Hamburg) 
Mini SDS-PAGE 
system 
Mini Protean 3 
electrophoresis cell 
Biorad (Munich) 
Power supply SX 250 mighty slim Hoefer (San Francisco, USA) 
Semi-Dry Transfer Cell Trans Blot SD Biorad (Munich) 
Shaker KS 10 Edmund Bühler (Tübingen) 
Shaker Vortex VF2 Janke und Kunkel IKA 
Labortechnik (Staufen) 
Sterilizer Varioclav Steam 
Sterilizer 
H+P Labortechnik GmbH 
(Oberschleißheim) 







Transilluminator 2UVTM MBT-Brand (Heidelberg) 
Ultracentrifuge CO TLX 120 Beckmann (Palo Alto, USA) 
UV/VIS microplate 
reader 
SPECTRAmax 340 Molecular devices 
(Sunnyvale, USA) 
Water bath Typ 1013 Gesellschaft für Labortechnik 
mbH (Burgwedel) 






Software Version Producer 
Adobe Acrobat reader 6.0 Adobe system (San Jose, USA) 
Adobe Photoshop 7.0 Adobe system (San Jose, USA) 
Endnote 6.0 ISI research software (Berkley, 
USA) 
Fluoroscan Ascent FL 2.4 Thermo labsystems (Vantaa, 
Finland) 
IBJ-Amon vitro dat 3.4 Jaeckel (Hanau) 
IBJ-Bemon vitro dat 3.4 Jaeckel (Hanau) 
Isis Draw 2.5 MDL Information Systems (San 
Ramon, USA) 
Kodak 1D Image Analysis  3.5 Eastman Kodak company (New 
Haven, USA) 
Leica FW 4000  1.1 Leica (Wetzlar) 
Mac OS X 10.3.9 Apple (Cupertino, USA) 
MacVektor 7.2 Accelrys (San Diego, USA) 
Microsoft Office for Mac 2004 Microsoft Deutschland GmbH 
(Unterschleißheim) 




1.2.0 Molecular devices (Sunnyvale, 
USA) 
 
4.3 Animal models 
 
Spontaneously hypertensive rats (SHR) developed at Okamato, Kyoto School 
of Medicine, in the 1960s by selective mating of hypertensive Wistar rats from 
the Kyoto School of Medicine (WKY rats) were used. SHR are a widely used 
animal model for essential hypertension. Inbred WKY rats have the same 
background and are thus the appropriate control for SHR. 




Animals were purchased from Charles River Laboratories (Sulzfeld). They 
were maintained in the animal facilities of the Rudolf-Buchheim-Institute, 
Giessen and fed standard rodent chow and water ad libitum. Male SHR and 
WKY rats at the age of 12-14 month were used throughout the studies. 
 
4.4 Organ preparation 
 
Krebs Henseleit buffer 
118 mM NaCl 
4.7 mM KCl 
2.5 mM CaCl2 • 2H20 
1.18 mM MgSO4 • 7H20 
1.18 mM KH2PO4 
24.9 mM NaHCO3 
pH 7.4 
 
Rats were killed by CO2 inhalation and thoracic aortae were carefully excised, 
dissected and placed in chilled Krebs-Henseleit buffer (pH 7.4). Adherent 
tissues as well as contaminating blood were carefully removed. 





Alcian blue solution 
1 g  Alcian blue 8GX 
3 ml  Acetic acid 
97 ml  Aqua dest. 
 
Nuclear fast red solution 
25 g  Aluminium sulfate 
0.5 g  Nuclear fast red 
500 ml Aqua dest. 




Weigert’s iron hematoxylin solution 
Sol. A: 1g  Hematoxylin in 100 ml 96% ethanol 
Sol. B: 1,16g FeCl3 
  99 ml Aqua dest. 
  1 ml Conc. HCl 
 
Azophloxin solution 
0,5 g  Azophloxin 
100 ml Aqua dest. 
0,2 ml  Acetic acid 
 
Phosphotungstic acid/ orange G solution 
3-5 g  Phosphotungstic acid 
2 g  Orange G 
100 ml Aqua dest. 
 
Light green solution 
0,2 g  Light green 
100 ml Aqua dest. 
0,2 ml  Acetic acid 
 
Orcein solution 
1 g   Orcein 
100 ml 70% Ethanol 
1 ml   HCl conc. 
 
Picroindigocarmin solution 
0,5 g  Picroindigocarmin 
200 ml Picric acid (saturated) 
 
 




Aortic segments of SHR (n=6) and WKY (n=6) were fixed in 4% buffered 
formaldehyde for 24 h, dehydrated in a graded series of ethanols and 
embedded in paraffin wax (melting point 58°C). Tissue segments were cut 
into 7 µm sections using a microtome, dewaxed in Rotihistol® and rehydrated 
in a graded series of ethanols.  
Alcian blue staining according to the method of Steedmann (Romeis, 1989) 
combined with nuclear fast red counterstaining was used for selective 
demonstration of acidic mucosubstances. The hydrated sections were bathed 
in 3% acetic acid for 3 min, stained with 1% Alcian blue solution (pH 3) for 30 
min and rinsed for 1 min in 3% acetic acid. Subsequently, sections were 
counterstained with nuclear fast red solution for 5 min, washed, dehydrated, 
cleared and covered with Rotihistokit®.  
 
 Acidic mucins/mucosubstances: blue 
 Nuclei:    reddish pink 
 
Masson’s trichrome staining, according to a slightly modified method of 
Goldner (Romeis, 1989), was performed to differentiate between muscle and 
collagen fibres. Hydrated slides were first stained with Weigert’s iron 
hematoxylin solution (nuclei) for 3 min. After washing for 10-15 min, slides 
were stained with azophloxin for 5 min (cytoplasma) and rinsed in 1% acetic 
acid. Subsequently, aortic sections were bathed using phosphotungstic acid/ 
orange G for 20 min and rinsed again in 1% acetic acid. Finally, slides were 
incubated with light green for 5 min to stain collagen fibres. After rinsing with 
1% acetic acid, slides were dehydrated, cleared and covered with 
Rotihistokit®. 
 
 Nuclei:    brownish black 
 Muscle fibres:   red 
 Collagen fibres:   green 
 
Elastic fibres were visualized according to the method of Taenzer and Unna 
using orcein staining combined with picroindigocarmin counterstaining 




(Romeis, 1989). Hydrated slides were stained with 1% orcein solution for 30 
min, differentiated with 80% ethanol and counterstained with 
picroindigocarmin solution for 15 min. After rinsing with 3.5% acetic acid, 
slides were dehydrated, cleared and covered with Rotihistokit®. 
 
 Nuclei, elastic fibres :  brown-red 
 Muscle fibres :   yellow 
 Collagen fibres:   blue-green 
 
Images were obtained with a Leica DM 6000B microscope equipped with a 
Leica DC 320 camera and the Leica FW4000 software was used for 
calculation of the aortic wall thickness. 
 
4.6 In situ ROS detection using DHE fluorescence 
 
Phosphate-buffered saline (PBS) 
2.7 mM KCl 
1.5 mM KH2PO4 
137 mM NaCl 
8 mM  Na2HPO4 
pH 7.4 
 
Thoracic aortae were embedded in Tissue Tek O.C.T. Compound. Non-fixed 
frozen cross sections (5 µm) were incubated with 5 µM DHE in a light-
protected moist chamber at 37°C for 30 min. Serial sections were treated with 
the inhibitors indicated for 30 min before incubation with DHE. Images were 
obtained with a Leica DM 6000B fluorescence microscope using the same 
imaging settings in each case. For semi-quantitative analysis of superoxide 
production, three to six images were acquired from three sections per aortic 
ring and sampled for each experimental condition. Images were analyzed with 
the Leica FW4000 software and changes in total fluorescence intensity were 
calculated as percent of SHR control. 
 




4.7 NADPH-derived lucigenin chemiluminescence 
 
Krebs HEPES buffer 
118 mM NaCl 
4.7 mM KCl 
2.5 mM CaCl2 • 2H20 
1.18 mM MgSO4 • 7H20 
1.18 mM KH2PO4 
24.9 mM NaHCO3 
11 mM Glucose 
0.03 mM EDTA 
20 mM HEPES 
1x  Complete EDTA-free protease-inhibitor cocktail 
pH 7.4 
 
NADPH-dependent O2− production was measured in aortic homogenates 
using a chemiluminescence based assay containing 5 µM lucigenin, a 
concentration that does not appear to be involved in redox cycling (Munzel et 
al., 2002). Aortae were snap frozen in liquid nitrogen and stored at -80°C. 
After mincing in liquid nitrogen, aortic homogenates were collected in 0.5 ml 
Krebs-HEPES buffer. The homogenates were centrifuged with 1000g (4°C, 
10 min) to remove cell debris, and the protein contents of the supernatants 
were determined by means of Micro-Lowry (detailed later). 100 µl reaction 
mixture containing 50 µg protein and 5 µM lucigenin in Krebs-HEPES buffer 
were transferred to individual wells of an opaque white 96 well plate and 
incubated for 30 min in the dark. Following addition of the substrate NADPH  
(100 µM), NADPH oxidase activity was measured using a luminescence plate 
reader (Fluoroskan Ascent FL) in the absence and presence of the 
substances indicated. Changes in chemiluminescent signals were calculated 
as percent of SHR control. 
 




4.8 RNA analysis 
 
4.8.1 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
 
Running buffer (TAE buffer) 
40 mM Tris 
20 mM Glacetic actic acid 
0.05 mM EDTA  
pH 8 
 
Total RNA was isolated from aortic homogenates using the RNeasy Mini Kit 
(see Table 4.1) according to the manufacturer`s protocol. RNA (100 ng) was 
reverse transcribed using Superscript III (see Table 4.2) according to the 
manufacturer`s protocol using Random Hexamers (250 ng/µl). Subsequently, 
probes were treated with RNase H (see Table 4.2) for 20 min at 37°C. PCR 
was performed using specific primers for rat Nox1, 2 and 4 and β-actin as 
housekeeping gene. The sequences for the specific genes were obtained 
from GenBank (NIH genetic sequence data base) and are shown in Table 
4.3. Amplification was carried out using a thermocycler with Platinum Taq-
polymerase (see Table 4.2). PCR was performed using the following 
conditions: after initial denaturation for 5 min at 94°C, 35 cycles of 1 min at 
94°C, 1 min at 59°C and 30 sec at 72°C were conducted followed by a final 
extension for 10 min at 72° C. Amplified PCR products were separated on a 
1.2% agarose gel in TAE buffer, stained with ethidium bromide and visualized 
and photographed under ultraviolet light. 
 
Method Kit Company 
RNA isolation RNeasy/ QIAshredder Qiagen (Hilden) 
Gel purification SNAP Gel Purification Kit Invitrogen (Karlsruhe) 
Subcloning TOPO TA Cloning Kit Invitrogen (Karlsruhe) 
Plasmid isolation QIA prep Spin Miniprepkit Qiagen (Hilden) 
 
Table 4.1: Kits used for RT-PCR and subcloning of PCR products 




Method Enzyme Company 
RT-PCR Superscript III Invitrogen (Karlsruhe) 
RNA digestion RNase H Invitrogen (Karlsruhe) 
PCR Platinum Taq Polymerase Invitrogen (Karlsruhe) 
Plasmid digestion EcoRI Roche (Mannheim) 
 
Table 4.2: Enzymes used for RT-PCR and subcloning of PCR products 
 
Gene Primer sequence 
Nox1 Fwd: 5‘ –CCT GCT CAT TTT GCA ACC AC - 3‘ 
Rev: 5‘ -CAT GAG AAC CAA AGC CAC AG -3‘ 
Nox2 Fwd: 5‘ -GAC AGA CTT CGG ACA GTT TG - 3‘ 
Rev: 5‘ -ACT CTA GCT TGG ATA CCT GG -3‘ 
Nox4 Fwd: 5‘ -GTG TTT GAG CAG AGC TTC TG – 3‘ 
Rev: 5‘ -GTG AAG AGA AGC TTT CTG GG -3‘ 
β-actin Fwd: 5‘ -GAA GTA CCC CAT TGA ACA CG - 3‘ 
Rev: 5‘ -CGC GTA ACC CTC ATA GAT GG -3‘ 
 
Table 4.3: Primers against rat Nox1, Nox2, Nox4 and β-actin used for RT-PCR  
 
4.8.2 Subcloning of Nox1, Nox2 and Nox4 
 
XIA Agar 
1.5%  Agar 
1%  Casein-hydrolysate 
0.5%  Yeast extract 
0.5%  NaCl 
200 µg/ml  Ampicillin 
50 µg/ml  IPTG   
40 µg/ml  X-Gal 
 





1%  Casein-hydrolysate 
0.5%  Yeast extract 
1%  NaCl 
200 µg/ml  Ampicillin 
 
 
PCR fragments were isolated from agarose gels and purified using the SNAP 
Gel Purification Kit (see Table 4.1) according to the manufacturers protocol. 
Subsequently, the purified PCR products were cloned by the TOPO TA 
Cloning Kit (see Table 4.1) into the pCR®2.1-TOPO®3.9kb vector according to 
the manufacturers protocol (bacteria strain: E. coli TOP10F’). 
Positive/negative selection of the subclones was carried out with XIA plates. 
Positive clones were incubated for 18h in liquid LB medium supplemented 
with ampicillin at 37°C and 220 rpm. Plasmids were isolated using the QIA 
Prep Spin Miniprepkit (see Table 4.1) according to the manufacturers 
protocol. Plasmids were digested with the restriction enzyme EcoRI (see 
Table 4.2) for 1h at 37°C and restriction products were visualized after 
agarose gel electrophoresis. Positive clones were outsourced for sequencing 

















4.9 Protein analysis 
 
4.9.1 Preparation of samples for Western blot analysis 
 
Triton lysis buffer 
20 mM Tris 
150 mM  NaCl 
10 mM Na-Pyrophosphat 
1 %   Triton X 100 
2 mM  Orthovanadat 
10 nM  Okadeic acid 
230 µM  PMSF 
1x  Roche Protease Inhibitor Mix (Complete EDTA-free - tablet) 
pH 7.5 
 
Aortae were snap frozen in liquid nitrogen and stored at -80°C. After mincing 
in liquid nitrogen, rat aortic tissue powder was lysed in 2x Triton lysis buffer 
with a protease inhibitor cocktail for 10 min on ice. Approximately 250 µl buffer 
was used for 30 mg frozen tissue. The mixture was vortexed and diluted 1:2 
with SDS-containing Rotiload® 4x (1:2 diluted in aqua dest.). Samples were 
heated under these reducing conditions for 10 min at 95°C in an Eppendorf 
thermo-mixer. After centrifugation at 8000g for 10 min, the supernatants were 
further analyzed. 
 
4.9.2 Protein determination (Micro-Lowry) 
 
Rotiload® sample buffer (Rotiload® 4x) 
62.5 mM Phospate buffer (pH 6.8) 
10% (v/v) Glycerol 
2% (w/v) SDS 
0.01% (w/v) Bromophenol blue 
5% (v/v) β-Mercaptoethanol 





Folin 1 solution 
Folin 1 is a mixture of the solutions A to D in a ratio of 1:1:28:10. 
Solution A: 1% (w/v) CuSO4 • 5H20 
Solution B: 2% (w/v) Di-sodium tartrate • 2H20 
Solution C: 3.4% (w/v) Na2CO3 
  0.2 M  NaOH 
Solution D: 10% (w/v) SDS 
 
Following precipitation of the Rotiload®-lysed proteins by trichloroacetic acid, 
protein content was determined using the protocol of Lowry et al. (Lowry et 
al., 1951; Peterson, 1977). Samples (10 µl) were diluted with 1 ml distilled 
water and 100 µl of 0.15% (w/V) deoxycholic acid was added. After 10 min 
incubation (all incubation steps were performed at room temperature on an 
Eppendorf shaker), 100 µl of 72% trichloroacetic acid was added followed by 
15 min incubation. The samples were centrifuged at 16000g for 10 min, the 
supernatants were removed and the pellets resolved in 300 µl water and 300 
µl Folin 1 solution. After an incubation step of 10 min, 150 µl of 25% Folin-
Ciocalteu`s phenol reagent was added and samples were incubated for 
further 30 min. Subsequently, the optical density of the samples was 
measured at 595 nm with a UV/VIS microplate reader and the protein 
concentration was calculated using BSA protein standards. 
 
4.9.3 PNGase F digestion 
 
Protein (150 µg) of aortic homogenates lysed in Triton lysis buffer was 
denatured by heating at 95°C for 10 min. Subsequently, samples were cooled 
to RT, 0.5% N-octyl glucoside and 50 units PNGase F were added and this 
mixture was incubated overnight at 37°C. Finally, Rotiload® buffer was added 
to the samples and Western blot analysis was performed as described below. 
 




4.9.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Electrophoresis buffer 
25 mM Tris 
120 mM Glycin 
0.1% (w/v) SDS 
pH 8.3 
 
Equal amounts of protein (40 µg) were separated by SDS-PAGE using 9% 
polyacrylamide gels (for composition see Table 4.4) according to the method 
described by Laemmli (Laemmli, 1970). Gels of 1 mm thickness and a size of 
8 x 9.5 cm were generated with a Biorad gel caster. After loading the 
samples, electrophoresis was performed at RT in a mini-SDS-PAGE system 
with a constant current of 15 mA/gel (stacking gel) and 20 mA/gel (resolving 
gel) using the power supply SX 250 mighty slim. Protein molecular weight 
standards were used as indicated under Table 4.5. 
 
Stacking gel Resolving gel 9% 
5% (v/v) Rotiphorese® Gel 30 9% (v/v) Rotiphorese® Gel 30 
80 mM Tris pH 6.8 375 mM Tris pH 8.8 
0.1% (v/v) SDS 0.1% (v/v) SDS 
0.05% (v/v) TEMED 0.05% (v/v) TEMED 
0.07% (w/v) APS 0.05% (w/v) APS 
 
Table 4.4: Gel compositions for SDS-PAGE. 
 
Marker Source 
PeqGOLD protein marker IV PeqLab Biotechnologie (Erlangen) 
Prestained Protein marker Biolabs (Frankfurt a.M.) 
 
Table 4.5: Protein markers used for Western blot anlysis. 




4.9.5 Western blotting 
 
Blotting buffer 
48 mM Tris 
39 mM Glycin 
0.1% (w/v) SDS 
20% (v/v) Methanol 
pH 8.5 
 
Ponceau S staining solution 
0.1% (w/v) Ponceau S 
5% (v/v) Acetic acid 
 
Tris-buffered saline with Tween 20 (TBS-T) 
20 mM Tris 
150 mM NaCl 
0.1% (w/v) Tween 20 
pH 7.5 
 
Proteins were transfered from resolving gels to a Hybond-ECL nitrocellulose 
membrane (Amersham Pharmacia Biotech, Freiburg) by semi-dry blotting (1.2 
mA/cm2 for 75 min). The transfer was performed in the Semi-Dry Transfer Cell 
Trans Blot SD using the blotting buffer mentioned above. 
Equal rates of transfer were confirmed by reversible staining with Ponceau-S 
solution. Blots were washed in aqua dest., stained for 5 min at room 
temperature and washed again with aqua dest.. Imaging was performed using 
the DiAlta di 351 copy machine. 
Non-specific binding to the membranes was blocked by incubation with 2.5% 
non-fat dry milk powder (Nestlé, Glandale, CA, USA) in Tris buffered saline 
containing Tween-20 (TBS-T) for 2 h at room temperature. Primary antibodies 
(see Table 4.6) were diluted in 2.5% milk/TBS-T and membranes were 
incubated at 4° C overnight. Subsequently, these membranes were washed 5 




times for 8 min with TBS-T and incubated with horseradish peroxidase 
conjugated secondary antibody (diluted as indicated in Table 4.7) for 1 h in 
the dark at RT. After washing with TBS-T (5x for 8 min in the dark), 
membranes were incubated either with ECL or with ECL advanced 
(Amersham Pharmacia Biotech, Freiburg, Germany) for 1 min and 5 min, 
respectively. Immunoreactive chemiluminescence signals were captured 
using the Kodak Imager Station 440CF which has a much higher saturation 
level (64000 grey levels) than traditional films (256 grey levels). Quantification 
of the light signals was performed using the Kodak ID image analysis 
software. 
 
Antibody Species Source Method Dilution 
Anti-Nox1 
(polyclonal) 




































Mouse Sigma (Deisenhofen, Germany) IF 1:400 
RECA-1  
(monoclonal) 
Mouse Serotec (Düsseldorf, Germany) IF 1:100 
 
Table 4.6: Primary antibodies used for Western blotting (WB) and immunofluorescence 
(IF). Nox1 and Nox4 antibodies were affinity-purified. 
 





Antibody Species Conjugation Source Method Dilution 








Goat HRPO Dako 
(Hamburg) 
WB 1:2000 





Donkey Cy3 Chemicon 
(Hofeheim) 
IF 1:200 













62.5 mM Tris 
2% (w/v) SDS 
100 mM β-Mercaptoethanol 
pH 6.8 
 
”Stripping” is a method for re-using a Western blot: the nitrocellulose 
membrane was incubated with 10 ml of stripping buffer in a water bath at        
60-70°C for 30 min to remove primary and secondary antibodies. After 
washing with TBS-T for 4 x 15 min, the membranes were ready for the next 











Aortic segments were embedded in Tissue Tec O.C.T. Compound (Sakura 
Finetek, Torrance, USA) and stored at -80°C until use. Tissues were 
sectioned to an average thickness of 7 µm with a Leica 1900 cryostat 
(Bensheim, Germany). After fixing with ice-cold acetone (10 min), sections 
were blocked with 10% normal goat serum (DAKO, Hamburg, Germany) 
containing 5% bovine serum albumine (Sigma, Deisenhofen, Germany). 
Incubations with the primary antibodies used in the concentrations indicated in 
Table 4.6 (diluted in PBS (pH 7.4) containing 0.1 %Triton X-100) were 
performed at 4°C for 24 h. Incubations with the secondary antibodies used in 
the concentrations indicated in Table 4.7 (diluted in PBS/Triton) were done at 
RT for 2 h. Immunoreactivity was visualized by fluorescence microscopy. In 
addition, double fluorescence labeling was performed with the FITC 
conjugated α-smooth muscle actin antibody and/or a RECA-1 antibody. For 
nuclear staining, the Hoechst dye 33342 was used. Serial sections were 
treated with the secondary antibodies alone as control for non-specific 
staining. 
 
DHE staining combined with immunofluorescence was performed as follows: 
aortic sections were stained with DHE as described above (see chapter 4.6) 
and subsequently blocked with 50% normal goat serum in PBS/Triton. 
Incubations with the primary antibodies (see Table 4.6) were done at 4°C for 
24 h in a moist chamber. Immunoreactivity was visualized by fluorescence 
microscopy using the secondary FITC conjugated antibodies (RT, 2 h) as 










4.11 Isometric force measurement 
 
Aortae were cut into rings (2-3 mm) and mounted on individual organ baths 
containing 5 ml of Krebs Henseleit buffer (pH 7.4). The solution was 
continuously oxygenated with a 95% O2 – 5% CO2 mixture and maintained at 
37°C. Changes in isometric tension were detected by a force transducer and 
recorded via a 6-channel transducer data acquisition system. During an 
equilibration period of 90 min the resting tension was gradually increased to 
20 mN and the buffer was exchanged every 15 min. The aortic rings were 
then challenged 1-2 times with 80 mM KCl to determine the viability of the 
rings and to activate them. After a regeneration phase of at least 45 min, rings 
were precontracted submaximally (60-80%) with 300-1000 nM phenylephrine. 
Concentration response curves (CRC) and Emax values were generated in the 
plateau phase of the phenylephrine contraction for the endothelium-
dependent vasodilator acetylcholine (1 nM – 10 µM in semi-logarithmic steps) 
in the absence and presence of apocynin (100 µM) or VAS2870 (10 µM). 
After the generation of the first CRC, rings were washed 3 times and allowed 
to regenerate for at least 45 min before performing the second CRC. 
 
4.12 Statistical analysis 
 
Statistical differences between the means were analyzed by Student´s t-test. 
For multiple comparisons, one-way analysis of variance (ANOVA) followed by 
Bonferroni´s multiple range test was employed. A value of p<0.05 was 
considered significant. Asterisks represent significance as follows: * p<0.05, ** 






5.1 Common characteristics of the animals 
(body weights, cytomorphology and contractility of aortae) 
 
In order to characterize the animal model investigated in this study, body 
weights were measured directly after sacrificing the animals. Surprisingly, 12-
14 month old male SHR weighed significantly less than their age-matched 
WKY controls (SHR: 381.6 ± 3.9 g (n=11), WKY: 547.9 ± 10.8 g (n=11), 
p<0.001).  
Chronic hypertension is supposed to be accompanied by a remodeling of 
vessels. Indeed, as shown in Figure 5.1 all histological staining methods that 
were performed point to major structural changes in the aortic wall of SHR in 
comparison to WKY. Alcian blue staining for acidic mucosubstances revealed 
increased accumulation of extracellular matrix proteins in SHR. Masson´s 
trichrome staining confirmed these findings and demonstrated partially 
enriched inclusions of connective tissue in the aortic media indicating a 
discrepancy in the occurence of medial muscle and collagen fibres between 
SHR and WKY. Furthermore, elastica staining revealed reduced numbers as 
well as structural differences in the elastic fibres in the aortic wall of SHR in 
contrast to WKY. These findings, which suggest a pathological modification of 
the vessel by increased extracellular matrix deposition and stiffness, were 
finally supplemented by the evaluation of the thickness of aortic intima and 
media. Analysis of the images obtained from the individual stainings exhibited 
an increased wall thickness in SHR (133.8 ± 1.4 µm) in comparison to WKY 








Figure 5.1: Structural changes in the aortic wall of SHR. In comparison to the aorta of 
WKY rats (A), alcian blue staining revealed an increased accumulation of ECM proteins (blue) 
in the intimal (arrow) as well as the medial layer (arrowhead) of SHR aorta (B). Nuclei were 
counterstained with nuclear fast red (red). The middle panels show Masson’s trichrome 
staining. Compared to WKY aortae (C), the aortic media of SHR (D) displayed an increased 
amount of connective tissue and/or collagen fibres (green, arrowhead), whereas the amount 
of muscle fibres (red, arrow) was partially decreased. Elastica staining demonstrated a 
decline of elastic fibres (arrow) in SHR aorta (F) in comparison to WKY aorta (E). Images are 
representative for n = 6 observations for each staining method. 
 
In line with these histological findings, the contractile response was decreased 
in SHR aortic rings in comparison to their WKY controls. Aortic rings were 





of the SHR aorta was diminished to 72% and 75% of the WKY contraction, 
respectively (Table 5.1). 
 
 
Table 5.1: Diminished contractility of SHR aortic rings.  Contraction response to 120 mM 
KCl or 10 µM PE was significantly lower in SHR aortic rings in comparison to their 
normotensive WKY controls (results are expressed as mean ± SEM, n=18, unpaired 
Student’s t-test) 
 
5.2 ROS generation in SHR and WKY aortae 
 
In order to investigate whether the essential hypertension is accompanied by 
oxidative stress, ROS production within the aortic wall was determined using 
dihydroethidium (DHE). In addition, the signal was specified and the main 
sources of ROS production were identified by preincubation with certain ROS 
scavengers or enzyme inhibitors. Figure 5.2 shows representative images of 
the assay. SHR aortic tissue exhibited a clearly visible increase of 
fluorescence intensity in comparison to WKY indicating enhanced oxidative 
stress in these animals. Semi-quantitative analysis of the images revealed a 
5.7 ± 1.3 fold higher signal intensity (Figure 5.3). The fluorescence, which is 
derived from the intercalation of oxidated DHE products with DNA, was 
enhanced in all layers of the SHR vessel. The superoxide  scavenger  tiron   
(1 mM) and the cell-permeable PEG-ylated superoxide dimutase (PEG-SOD, 
250 U/ml) completely suppressed the increased fluorescence in SHR aortae 
indicating that superoxide is the predominant ROS responsible for oxidative 










Figure 5.2: Increased superoxide production in SHR aortic sections is prevented by 
NADPH oxidase inhibition. Aortic segments of WKY and SHR were incubated with DHE in 
the absence and presence of the substances indicated. In comparison to WKY (A), ROS 
production was significantly increased in SHR (B). Tiron (C, 1 mM), DPI (D, 10 µM) and the 
NADPH oxidase inhibitors VAS2870 (E, 10 µM) and apocynin (F, 1 mM) suppressed the ROS 
production in SHR aortae, whereas the NOS inhibitor L-NAME (G, 1 mM) and the XOD 
inhibitor oxypurinol (H, 100 µM) had no or rather weak effects on fluorescence intensity. 
Images are representative for n=6 observations. 
 
Furthermore, this production of superoxide can be predominantly attributed to 
flavoenzymes, because DPI (10 µM) effectively inhibited the signal in SHR 
aortae. Incubation with the NADPH oxidase inhibitors VAS2870 (10 µM) and 
apocynin (1 mM) significantly suppressed the fluorescence intensity in all 
layers of the SHR aorta indicating NADPH oxidase as the predominant source 
of oxidative stress. The novel compound VAS2870 completely eliminated the 
increased ROS production in all vascular layers of SHR aortae, whereas 
apocynin partially inhibited the signal even with the relatively high 
concentration of 1 mM. In contrast to the NADPH oxidase inhibitors, the NOS 
inhibitor L-NAME did not suppress the ROS production but rather showed a 
slight upregulation of ROS generation in the adventitia. However, the semi-
quantitative analysis of the images could not confirm this observation. Finally, 
the contribution of XOD was estimated by incubating aortic sections with 
oxypurinol. The fluorescence was slightly affected by this inhibitor, especially 
in the adventitia, but this suppression did not reach statistical significance with 
semi-quantitative analysis. All compounds were tested in parallel in WKY 
aortic segments, but did not exhibit any statistically significant effects, 
probably due to the weaker ROS production in the organs of these animals 
making it difficult to detect any effects on the fluorescence intensity (data not 
shown). In summary, these data suggest a major role of NADPH oxidase in 







Figure 5.3: Semi-quantitative analysis of ROS production detected with DHE. 
Fluorescence intensity was quantified and shown as percent of the signal of untreated WKY 
aortic rings. ROS production in WKY was significantly lower than in SHR aorta. Tiron (1 mM), 
PEG-SOD (250 U/ml), DPI (10 µM), VAS2870 (10 µM) and apocynin (1 mM) significantly 
attenuated the signal in SHR segments, whereas L-NAME (1 mM) and oxypurinol (100 µM) 
had no significant effects. Values are mean ± SEM, n=6 (**p<0.01, ***p<0.001) 
 
5.3 NADPH oxidase activity in SHR and WKY aortae 
 
To verify the results obtained in the DHE assay, NADPH oxidase activity was 
measured in aortic homogenates of SHR and WKY rats. As shown in Figure 
5.4, NADPH-derived lucigenin (5 µM) chemiluminescence was significantly 
higher in aortic homogenates of SHR compared to WKY. This signal was 
suppressed by tiron (1 mM) indicating that superoxide was the main ROS 
detected in this assay. Inhibition by the flavoenzyme antagonist DPI (10 µM) 
as well as by the NADPH oxidase inhibitors VAS2870 (10 µM) and apocynin 





superoxide production in SHR. As expected, neither the NOS inhibitor L-
NAME nor the xanthine oxidase inhibitor oxypurinol interfered with the 
chemiluminescence signal ruling out a significant contribution of these 
putative ROS sources. None of the above mentioned substances showed a 
significant suppression of the signal in homogenates of WKY aortae (data not 
shown). In summary, these results demonstrated that NADPH oxidase activity 
was enhanced in the aortic homogenates of 12-14 month old male SHR. 
 
 
Figure 5.4: NADPH-derived lucigenin chemiluminescence. NADPH-derived ROS 
production was measured using 5 µM lucigenin and expressed as percent of the 
chemiluminescence signal generated in WKY aortic homogenates. ROS production was 
significantly lowered in WKY in comparison to SHR. Tiron (1 mM), DPI (10 µM), VAS2870 (10 
µM) and apocynin (100 µM) suppressed the chemiluminescence signal in SHR homogenates, 







5.4 mRNA expression of Nox isoforms in aortic homogenates 
 
Expression of Nox1, Nox2 and Nox4 mRNA was determined in aortic 
homogenates to investigate the occurence of the vascular Nox isoforms in 12-
14 month old male SHR and WKY rats. Reverse transcriptase polymerase 
chain reaction (RT-PCR) was performed and confirmed the expression of 
Nox1, Nox2 and Nox4 in aortae of SHR as well as WKY (Figure 5.5).  
 
 
Figure 5.5: mRNA expression of Nox isoforms in SHR and WKY aorta. RT-PCR analysis 
indicated that Nox1, Nox2 and Nox4 are expressed in WKY aortae (A) and SHR aortae (B). In 
both strains Nox4 seemed to be higher expressed than Nox1 and Nox2. (Images are 
representative for n = 6 animals of both strains). 
 
 
5.5 Distribution of Nox isoforms in the aortic wall of SHR and WKY 
 
In order to visualize topographically in which layers of the vessel wall the Nox 
isoforms are located, aortae of SHR and WKY were investigated 
immunohistochemically.  
As shown in Figure 5.6, Nox1 protein was mainly detected in the media of the 
aortic wall with strong signals in the luminal situated cell layers of the media. 
Remarkably, the intima of SHR aortae showed a strong Nox1 
immunofluorescence, whereas no or at least very weak signals were found in 










Figure 5.6: Distribution of Nox isoforms in SHR and WKY aortae. Nox1 
immunofluorescence was detected in the media and weakly in the intima of WKY aortae (A). 
In contrast, Nox1 immunosignals in SHR aortae (B) were found in the media (arrowhead) and 
were increased in the intima (arrow). Nox2 protein was detected in the adventita and the 
intima of WKY aortae (C). The same expression pattern for Nox2 was found in SHR (D), 
where signals in the adventita (arrowhead) and the intima (arrow) are labeled. As shown for 
WKY (E) and SHR (F), Nox4 protein was found in all layers of the aortic wall with a strong 
signal in the adventitia (arrowhead) and the inner layers of the media (chevron). Signals in the 
intima (arrow) appeared to be comparatively less pronounced. Control experiments, where 
the primary antibody was omitted, are shown for WKY (G) and SHR (H). Antigen-antibody-
complexes were visualized with a Cy3-coupled secondary antibody leading to a red 
fluorescence and nuclei were counterstained with Hoechst 33342 (blue). L: lumen. Images 





Nox2 was detected in the adventitia and the intima of aortic sections, while 
the media appeared to be devoid of Nox2 protein. Both rat strains displayed 
the same distribution of this Nox isoform, which is in line with the expression 
of Nox2 in fibroblasts and EC, but not in VSMC of conduit arteries.  
Finally, Nox4 protein was found in all the three layers of the aortic wall with an 
apparently stronger staining in the adventitia. Interestingly, similar to the Nox1 
protein pattern, the luminal side of the media also exhibited an increased 















5.6 Quantitative Western blot analysis of aortic homogenates 
 
5.6.1 Nox1, Nox2 and Nox4 protein expression in SHR and WKY aortae 
 
Protein expression of the vascular Nox isoforms Nox1, Nox2 and Nox4 was 
assessed in the aortic homogenates of aged SHR and WKY rats to determine 
which of the catalytic NADPH oxidase subunits are involved in the increased 
oxidative stress observed in SHR. 
 
Figure 5.7 shows representative Western blots with the Nox1 antibody in 
aortic homogenates of SHR and WKY rats. The antibody detected a 60 kD 
band which is close to the predicted Nox1 protein size of 65 kD. Densitometric 
analysis of this band and normalization to the respective actin levels 
demonstrated a 3.4 ± 0.6 times higher expression of Nox1 in SHR compared 
to WKY aortae. However, the antibody detected two additional bands at 126 
kD and 138 kD and also a faint band at 50 kD (relative to the molecular weight 
standard). To test if these immunoreactive bands are specific, antibody 
binding was blocked by preincubation with the peptide used for immunization. 
As shown in panel B of Figure 5.7, the high molecular weight bands as well 
as the 60 kD band were no longer detectable after peptide blocking, which 
suggests that they were specific for the Nox1 antibody. In contrast, the faint 
50 kD band was not peptide-blockable pointing to a non-specific binding. To 
investigate whether the detected proteins were glycosylated, PNGase 
digestion was performed with aortic homogenates of SHR. This experiment 
indicated a slight glycosylation of the 60 kD band; there was no effect on the 








Figure 5.7: Nox1 protein expression in aortic homogenates of SHR and WKY rats. 
Representative Western blot showing Nox1 and related actin expression (A). Peptide block 
identifying three Nox1 positive protein bands at 60 kD, 126 kD and 138 kD in SHR aortic 
homogenates (B). PNGase digestion of SHR aortic homogenate revealed a glycosylation of 
the 60 kD band (C). Densitometric analysis of the 60 kD band demonstrated that Nox1 protein 
is significantly upregulated in SHR compared to the WKY aortic homogenate (D). Signals of 
the Nox1 band were normalized to actin and shown as percent of the level seen in WKY. 





Figure 5.8 shows Nox2 protein expression and respective β-actin levels in 
SHR and WKY aortic homogenates. A single band was detected at 75 kD, 
which was described as a glycosylated form of Nox2. Densitometric analysis 
and normalization to the actin standard revealed an upregulation of Nox2 
protein in SHR aortae (1.6 x ± 0.1, p<0.01) in comparison to the age matched 




Figure 5.8: Nox2 protein expression in aortic homogenates of SHR and WKY rats. 
Representative Western blot showing Nox2 and related actin expression (A). Densitometric 
analysis of Nox2 immunoblots (B). Signals were normalized to actin and expressed as 
percent of the level in WKY. Nox2 protein shows a significantly higher expression in SHR than 
in WKY aortic homogenates. Values represent means ± SEM of n = 6 animals. (**p<0.01) 
 
Finally, Nox4 protein expression was determined in the aortic homogenates of 
SHR and WKY rats. As shown in Figure 5.9 a single band was detected at 58 
kD with the polyclonal Nox4 antibody. Densitometric analysis of the blots and 
normalization to actin revealed no significant difference in Nox4 expression 









Figure 5.9 Nox4 protein expression in aortic homogenates of SHR and WKY rats. 
Representative Western blots showing Nox4 and related actin expression (A). Densitometric 
analysis of Nox4 immunoblots (B). Signals were normalized to actin and expressed as 
percent of the level seen in WKY. Nox4 protein levels were not statistically different in SHR 
compared to WKY aortic homogenates. Values represent means ± SEM of n = 6 (SHR) and n 
= 5 (WKY) animals. 
 
 
5.6.2 Expression of eNOS protein in SHR and WKY aortae 
 
Since eNOS is crucial in regulating vascular tone and endothelial function, we 
next compared the protein expression of this enzyme. Thus, Western blots 
with aortic homogenates of SHR and WKY were performed using a 
monoclonal antibody against eNOS. As shown in Figure 5.10, eNOS protein 
bands were detected at a molecular weight of 140 kD which is the expected 
molecular weight. Densitometric analysis and normalization to the respective 
actin levels revealed no statistical difference of eNOS expression between 








Figure 5.10: eNOS protein expression in aortic homogenates of SHR and WKY rats. 
Representative Western blot showing eNOS and related actin expression (A). The eNOS 
specific band was detected at 140 kD. The doubleband at 50 kD was not specific for the 
primary antibody, but was derived from the secondary antibody. Densitometric analysis of 
eNOS immunoblots (B). Signals were normalized to actin and shown as percent of the level in 
WKY. eNOS protein levels were not statistically different in SHR in comparison to WKY aortic 
homogenates. Values represent means ± SEM of n = 6 animals. 
 
5.7 Colocalization of Nox1 with α-SM-actin, RECA-1 and ROS formation 
 
While the localization of Nox2 protein in the aortic wall is well elucidated and 
could be confirmed in the present study, the protein expression patterns of the 
novel isoforms Nox1 and Nox4 are less explored in rat aortae. Thus, Nox1 
and Nox4 distribution was investigated in more detail by immunohistochemical 
colocalization with α-SM-actin, a marker for VSMC. As shown in Figure 5.11, 
Nox1 detection matches with the α-SM-actin localization in medial VSMC. 
However, in addition to the colocalization with α-SM-actin, SHR aortae 
exhibited a strong Nox1 immunosignal in α-SM-actin negative intimal cells 





aortae mainly expressed Nox1 in cells, which also expressed α-SM-actin, but 
not or very weak in intima and adventitia.  
Moreover, Nox4 immunosignals matched with the α-SM-actin immunostaining 
in SHR and WKY aortae demonstrating its expression in VSMC. Both strains 
displayed a strong Nox4 signal in α-SM-actin negative cells of the adventitia 
and to a smaller extend in the intima. Noticeable is that the enhanced Nox1 
and Nox4 immunofluorescence in the luminal situated layers of the media 
matched perfectly with α-SM-actin verifying that VSMC are the major side of 
Nox1 and Nox4 expression in SHR as well as WKY aortae. 
 
For further cytological characterization of the Nox1 immunofluorescence in 
SHR aortae, additional colocalization experiments were performed. Figure 
5.12 shows the colocalization with α-SM-actin as a marker for VSMC, with 
RECA-1 as a marker for endothelial cells and with oxidized DHE as a marker 
for ROS production. As already shown in Figure 5.11, Nox1 was detected in 
VSMC, but was also found in the α-SM-actin negative intimal layer of SHR 
aortae. The Nox1 immunosignal in the intimal layer matched well with the 
RECA-1 immunofluorescence verifying the Nox1 detection in EC. 
Furthermore, combination of immunofluorescence with DHE-mediated in situ 
ROS detection revealed the presence of Nox1 protein in ROS generating cells 
in the media as well as in the intima of SHR aortae. However, the DHE 
signals in the adventitia and partly in the intima did not match with Nox1 












Figure 5.11: Colocalization of Nox1 and Nox4 protein with α-SM-actin in SHR and WKY 
aortae. Images on the left show the detection of the Nox isoforms (red-orange fluorescence 
of the Cy3-coupled secondary antibody), images in the middle represent the α-SM-actin 
immunosignals (green fluorescence of the FITC-coupled secondary antibody), and images on 
the right show the merge of the stainings. Nox1 and α-SM-actin colocalization in SHR aorta 
(A). The merge of the two images revealed the expression of Nox1 in α-SM-actin positive 
cells of the media (yellow signal, arrowhead), but also in the α-SM-actin negative intimal 
(arrow) and adventitial layer (chevron). Nox1 immunofluorescence in the media of WKY aorta 
colocalizes with α-SM-actin (arrowhead), but there was none or at least a very weak signal in 
the intimal (arrow) and adventitial layer (B). Nox4 distribution was similar in the aortic wall of 
SHR (C) and WKY (D). Nox4 colocalizes with α-SMC-actin (arrowheads), but preferably in 
the luminal situated cell layers of the media. In addition, there is a strong positive Nox4 signal 
in the adventitia (chevrons) and in the intima (arrows), which do not merge with α-SM-actin. 
Control experiments where the primary antibodies were omitted are shown for SHR (E) and 










Figure 5.12: Colocalization of Nox1 protein with α-SM-actin, RECA-1 and oxidized DHE 
in SHR aortae. Images on the left show the detection of Nox1 (red-orange fluorescence of 
the Cy3-coupled secondary antibody and green fluorescence of the FITC-coupled secondary 
antibody, respectively), images in the middle represent the α-SM-actin or RECA-1 labeling 
(green fluorescence of the FITC-coupled secondary antibody) or the red fluorescence of 
oxidized DHE. Images on the right show the merge of the stainings. Nox1 and α-SM-actin 
colocalization in SHR aortae (A). Nox1 signals matched with α-SM-actin in the medial layer of 
SHR aorta (arrowhead), whereas the Nox1 fluorescence in the intima did not match (arrow). 
Control experiments, where the Nox1 antibody was omitted, indicated the specificity of the 
immunosignals (B). The intimal Nox1 signal matched with RECA-1 labeled EC (arrow, C). 
Control experiments, where the Nox1 antibody was omitted, indicated the specificity of the 
immunosignals (D). Nox1 was localized in ROS producing cells as demonstrated by DHE 
oxidation (E). Immunofluorescence and DHE signals matched in the media (arrowhead) and 
partly in the intima (arrow) of SHR aortae. However, there were also ROS generating cells 
showing no Nox1 immunofluorescence, mainly in the adventitia (chevron) and to some extend 
in the intima of SHR aortae. Control experiments with the secondary FITC-coupled antibody 
revealed the specifity of the Nox1 signals (F). L = lumen. Images are representative for n = 6 






5.8 Endothelial function in SHR and WKY aortae 
 
To test the hypothesis that NADPH oxidase-dependent oxidative stress is 
involved in aortic endothelial dysfunction of SHR, acetylcholine (ACh)-induced 
endothelium-dependent relaxation was investigated in aortic rings of SHR and 
WKY. As shown in Figure 5.13, the maximal relaxation response to ACh was 
indeed reduced in SHR aortae (SHR: 56.2 ± 1.1% versus WKY: 67.9 ± 2.7% 
of PE-induced contraction). The NADPH oxidase inhibitors apocynin (100 µM) 
as well as the novel compound VAS2870 (10 µM) significantly improved the 
endothelium-dependent relaxation in SHR aortae (77.8 ± 4.9% and 80.8 ± 
3.6% of PE-induced contraction, respectively). Remarkably, the maximal 
relaxation effect to ACh in WKY rats was significantly increased in the 
presence of apocynin or VAS2870 (79.4 ± 2.2% and 80.2 ± 2.6% of PE-
induced contraction, respectively) suggesting that also in this rat strain 
NADPH oxidases are involved in a reduction of NO bioavailability. However, 
NADPH oxidase inhibition leads to an increased endothelium-dependent 
relaxation of about 80% in both strains, which demonstrates that the 
improvement of relaxation is more pronounced in SHR. In addition, this 
indicates that indeed NADPH oxidases are involved in the impairment of the 
relaxation response to ACh in aortae of SHR. 
 
Moreover, VAS2870 and apocynin themselves displayed a strong direct 
relaxation activity (Figure 5.14) in aortic rings. This suggests that NADPH 
oxidase-derived ROS impede relaxation mechanisms also in the absence of 
stimuli of NO production. This effect seems to be more pronounced in SHR 
than in WKY aortae and is in line with a higher basal NADPH oxidase activity 
in this model. However, the higher relaxation activity in SHR reached 
significance only for apocynin, probably due to a higher variance that was 








Figure 5.13: VAS2870 and apocynin improved the impaired endothelium-dependent 
relaxation in SHR aortae. Acetylcholine (ACh)-induced relaxation was significantly impaired 
in aortic rings of SHR in comparison to WKY (as depicted in the control columns, which 
represent relaxation in the absence of any compound). The NADPH oxidase inhibitors 
VAS2870 (10 µM) and apocynin (100 µM) compensated the impaired relaxation response to 
ACh in SHR, but also led to an enhanced maximal relaxation in WKY aortic rings (values are 
means ± SEM, n≥5, *p<0.05, ***p<0.001 in comparison to WKY control, ###P<0.001 in 







Figure 5.14: Increased direct relaxation induced by NADPH oxidase inhibitors in SHR 
aortic rings. VAS2870 (10 µM) and apocynin (100 µM) directly dilated aortic rings (42.6 ± 
11.8 % and 38.4 ± 4.5% of PE-induced contraction, respectively), an effect that appeared to 
be more pronounced in SHR rings (57.5 ± 8.2% and 64.0 ± 3.9%, respectively). This increase 
in relaxation activity was significant for apocynin only (values are presented as means ± SEM,   






6.1 Contribution of NADPH oxidases to oxidative stress in aortae of 
SHR 
 
Hypertension is accompanied by oxidative stress in the vessel wall whereby 
NADPH oxidases, uncoupled eNOS and XOD are discussed as relevant 
sources of ROS generation (Cai & Harrison, 2000). The exact contribution of 
these individual enzymes is still a matter of debate. Thus, the involvement of 
these enzymes in aortic ROS production was investigated in aged SHR - an 
established model of chronic hypertension. 
In situ ROS production in rat aortae was detected using dihydroethidium 
(DHE). Oxidation of DHE results in the formation of ethidium, which binds to 
DNA and leads to a bright red fluorescence (Rothe & Valet, 1990; Miller et al., 
1998; Sorescu et al., 2002). This DHE signal was ~6 times higher in SHR than 
in WKY indicating increased ROS production in the aorta of these 
hypertensive animals. This is in line with several studies showing increased 
aortic superoxide formation measured with lucigenin chemiluminescence in 
SHR (Zalba et al., 2001; Ulker et al., 2003) as well as SHR-stroke-prone 
(SHR-SP) rats (Hamilton et al., 2001). Scavenging of superoxide by Tiron and 
and its dismutation by PEG-SOD reduced the ROS formation in SHR to the 
levels of WKY suggesting that indeed superoxide is the predominant species 
responsible for the signal. The NOS inhibitor L-NAME had no effect on DHE 
fluorescence indicating that uncoupled eNOS does not contribute to aortic 
ROS production in aged SHR. Oxypurinol which inhibits XOD seemed to 
slightly suppress the DHE signal, but this effect did not reach statistical 
significance probably due to the high variance observed in this semi-
quantitative assay. However, these data give evidence that XOD plays no or 
at least only a minor role in aortic ROS production.  
In contrast, NADPH oxidase was identified as the main source of ROS 
generation in the SHR model. On the one hand, the enhanced ROS formation 
in SHR was reduced to the levels of WKY in presence of DPI, apocynin and 





NADPH-induced lucigenin chemiluminescence was significantly enhanced in 
SHR aortae. In this context, it should be mentioned that DPI and VAS2870 
appeared to be more potent and more effective than apocynin in suppressing 
NADPH oxidase-mediated ROS formation in the DHE assay. A reason for this 
observation may be that a part of the NADPH oxidase activity measured is 
independent on p47phox translocation, which is suggested to be the targeted 
event of apocynin (Stolk et al., 1994; Meyer et al., 1999) and thus not 
inhibitable by apocynin. Furthermore, conversion of apocynin to its active 
metabolite could be insufficient depending on the conditions used in the assay 
(Stolk et al., 1994; Cifuentes & Pagano, 2006). However, the difference in 
efficacy between apocynin and VAS2870 was not significant in the DHE 
assay and could not be detected in the NADPH oxidase activity assay using 
lucigenin.  
The lucigenin assay revealed a twofold increase of NADPH oxidase activity in 
SHR aortic homogenates in comparison to WKY, a magnitude of activity that 
was also found by other groups (Zalba et al., 2000; Ulker et al., 2003). In 
contrast, the DHE assay revealed a nearly 6-fold increase in ROS production 
that was mainly caused by NADPH oxidase-derived superoxide. The reason 
for this discrepancy may be the different detection methods used. The DHE 
assay is based on the oxidation of DHE to ethidium which binds to DNA and 
gives a bright red fluorescence (excitation: 500-530 nm; emission: 590-620 
nm) (Sorescu et al., 2002). A recent publication showed that superoxide itself 
reacts with DHE to oxyethidium which represents a different fluorescent 
product (excitation: 480 nm; emission: 567 nm) and is overlayed by the 
ethidium fluorescence (Zhao et al., 2003). Since the superoxide scavengers, 
tiron and PEG-SOD, strongly inhibit the ethidium signal, the formation of 
ethidum appears to be caused by the reaction with other ROS (Fridovich, 
2003), in which superoxide is the progenitor. This in situ assay therefore 
reflects an indirect measure of superoxide. In contrast, lucigenin is suggested 
to react directly and specifically with superoxide (Munzel et al., 2002).  Taken 
together, these results indicate that the reactive products originating from 
superoxide are quantitatively more relevant than superoxide itself. Another 





detection method whereas the lucigenin assay was performed with 
homogenates and after addition of high amounts of the substrate, NADPH. 
Finally, both assays have their limitations. The DHE assay is semi-quantitative 
and the lucigenin assay, which was performed in a 96-wellplate-reader, is 
probably not as sensitive as other chemiluminescence-based methods. This 
could also be the explanation for the relative inefficiency of the superoxide 
scavengers and NADPH oxidase inhibitors to significantly suppress the basal 
ROS production in WKY aortae. However, the low signals detected suggest 
that there is no significant oxidative stress in aortae of these normotensive 
animals. 
In summary, these data suggest that NADPH oxidases are the major source 
of oxidative stress in the aortae of 12-14 month old SHR rats. The overactivity 
of this enzyme system in genetic hypertension was also shown in other 
organs such as mesenteric arteries and the kidney where increased ROS 
production was accompanied by upregulation of p47phox in the renal 
vasculature, macula densa and distal nephron (Touyz, 2004). Therefore, 
NADPH oxidases appear to be involved in ROS-mediated alterations of the 
cardiovascular system during hypertension and thus represent a promising 
target for retarding or even reversing these processes. 
 
 
6.2 Effect of NADPH oxidase inhibition on endothelial function 
 
Endothelial function was assessed by ACh-induced vasorelaxation of 
phenylephrine precontracted aortic rings. The relaxation response in SHR 
was significantly impaired in comparison to their normotensive controls 
indicating that the vascular NO bioavailability is decreased in these animals. 
Ulker et al. (2003) observed the same in aortae of 22 week old SHR and WKY 
and could show that preincubation of aortic rings with the antioxidants vitamin 
C and E prevents the impaired relaxation observed in SHR suggesting the 
involvement of ROS. Another study described that in vivo administration of the 
antioxidants, vitamins C and E or tempol, reversed the age-related reduction 





measured in 3 month old SHR. Furthermore, this enhancement of relaxation 
was eliminated by pre-treatment of the vessels with the eNOS inhibitor L-
NAME or an inhibitor of soluble guanylyl cyclase, ODQ (Payne et al., 2003). In 
summary, the data indicates that oxidative stress-mediated impairment of the 
NO-cGMP pathway leads to the diminished endothelium-dependent 
relaxation. 
To support the concept of oxidative stress-derived endothelial dysfunction 
seen in the aorta of SHR, vessels were treated with the NADPH oxidase 
inhibitors, apocynin and VAS2870, which resulted in a significantly improved 
vasorelaxation response to ACh. This suggests that NADPH oxidase-derived 
ROS decrease the endothelium-dependent relaxation by scavenging NO and 
thereby reducing its bioavailability. In another study similar experiments were 
performed with other NADPH oxidase inhibitors, namely DPI, PAO and 
AEBSF (Ulker et al., 2003). As expected, application of DPI impaired the ACh-
induced relaxation attributed to the fact that DPI also targets the flavoenzyme 
eNOS. The observed inefficiency of AEBSF and PAO can be explained by 
their non-specific actions, since PAO conjugates to vicinal sulfhydryl groups 
(Vignais, 2002) of many enzymes and AEBSF is a serine protease inhibitor 
(Diatchuk et al., 1997). In agreement with these results, Hamilton et al. (2002) 
showed that PAO and AEBSF were not able to increase NO bioavailability in 
carotid arteries of 9-12 month old WKY and SHR-SP. In contrast, PEG-SOD 
as well as apocynin were able to significantly improve NO bioavailability in the 
same study. The present work confirmed these findings for apocynin and, 
moreover, brings forth the new compound VAS2870 as an effective NADPH 
oxidase inhibitor that improves the endothelium-dependent aortic relaxation in 
SHR even in lower concentrations (10 µM) than apocynin (100 µM). 
Interestingly, the ACh-induced relaxation in WKY aortae was improved by 
apocynin and VAS2870, too. An explanation for this observation could be a 
NADPH oxidase-mediated and age-related development of endothelial 
dysfunction in these normotensive animals, although less pronounced than in 
SHR. Importantly, the 12-14 month old WKY rats showed a pronounced 
obesity (in average 170 g heavier than age-matched SHR), an observation 





raises the question whether WKY rats can be considered as an appropriate 
control in studies investigating endothelial dysfunction of SHR; however, it 
provides an explanation for an impaired relaxation, since it was also shown 
that obesity is accompanied with ROS-mediated endothelial dysfunction 
(Viswanad et al., 2006). Another likely possibility could be that NADPH 
oxidases contribute to the maintainance of vascular tension via 
counterbalancing the NO production under physiological conditions. Cai and 
Harrison (2000) hypothesized that there is always some superoxide reacting 
with NO even under basal conditions. Therefore, inhibition of the enzymatic 
source of superoxide would lead to an enhanced NO bioavailability and 
increased NO-mediated vasorelaxation. However, these interpretations 
remain speculative, since in the present study no significant suppression of 
ROS generation in WKY aortae could be detected using apocynin as well as 
VAS2870. The findings of Hamilton and colleagues would favour the second 
hypothesis for a physiological role of ROS in maintaining vascular tension, 
because they showed that apocynin improved NO bioavailability in young as 
well as aged WKY aortae (Hamilton et al., 2002). 
Apocynin as well as VAS2870 directly relaxed precontracted aortic rings of 
WKY and SHR. However, the relaxation response in SHR was more 
pronounced suggesting that the aortae of these rats exhibits a basal eNOS 
activity as well as an increased NADPH oxidase activity. This observation is in 
line with the hypothesis that NO is constantly scavenged by ROS generated 
by NADPH oxidases. Interestingly, Hamilton et al. (2002) could observe this 
direct relaxation effect in vessels of patients that underwent coronary artery 
revascularization and found that the apocynin-induced relaxation is more 
pronounced in veins than in arteries. However, whether this strong relaxation 










6.3 Expression of vascular Nox isoforms in aortae of SHR 
 
The phagocytic NADPH oxidase is a multimeric complex composed of two 
membrane integrated subunits, the catalytic subunit Nox2 and p22phox, and at 
least three cytosolic proteins, p47phox, p67phox and rac1/2 which translocate to 
the membrane upon activation (Babior, 1999). Vascular NADPH oxidases are 
structurally different. They contain one of the catalytic Nox homologues Nox1, 
Nox2 or Nox4 (Lassegue & Clempus, 2003) which all require p22phox for 
functional activity (Ambasta et al., 2004). The role of the cytosolic NADPH 
oxidase subunits for the individual Nox1, Nox2 or Nox4-comprising enzyme 
complexes is not clarified yet. Studies in p47phox knockout-mice gave evidence 
that this subunit could be involved in pathological ROS production such as 
found in angiotensin II-mediated hypertension (Landmesser et al., 2002). In 
aged SHR, expression of the membrane subunit p22phox was found to be 
upregulated on the mRNA (Zalba et al., 2000) as well as on the protein level 
(Hamilton et al., 2001) compared to their age-matched WKY controls. 
However, the role of the individual Nox isoforms in these animals has not 
been clarified yet and therefore Western blot analysis was performed using 
antibodies raised against Nox1, Nox2 or Nox4 in the present study. The Nox1 
as well as Nox2 protein was significantly upregulated in aortae of SHR, 
whereas there was no significant change in the level of Nox4 protein. This is 
the first study which shows that the increased NADPH oxidase activity in SHR 
is accompanied by increased protein expression of Nox1 and Nox2. Hamilton 
and colleagues investigated the mRNA expression of Nox1 and Nox2 in 
young and aged SHR and WKY, but they could not find any statistical 
differences. This might be due to the low n-number used in their study and the 
very low expression levels of Nox1 observed (Hamilton et al., 2002). In 
addition, it becomes apparent that the Nox expression levels differ rather at 
the protein than at the mRNA level. Furthermore, several studies are in 
agreement with an increased Nox1 and Nox2 expression in animal models of 
endothelial dysfunction. For example, angiotensin II infusion in C57B1/6 mice 
caused a marked upregulation of p67phox and Nox2 protein in the thoracic 





showed an increased Nox1 (6 to 7-fold), Nox2 (3-fold) and p22phox (3-fold) 
mRNA expression, whereas Nox4 mRNA was only marginally increased (1.5-
fold) compared to sham-treated rats (Mollnau et al., 2002). Moreover, aortae 
of diabetic rats, which exhibit endothelial dysfunction and increased oxidative 
stress, showed higher Nox1 protein and Nox2 mRNA levels, while Nox4 
protein levels remained unchanged in comparison to their respective controls 
(Hink et al., 2001; Wendt et al., 2005). Finally, a very recent study 
demonstrated that the endothelial dysfunction that was observed in mice 
deficient in BKβ1 (a subunit of a large conductance Ca2+-activated K+-
channel) was accompanied by oxidative stress, increased p67phox and Nox1 
protein expression and could be normalized by apocynin (Oelze et al., 2006). 
Studies in Nox2-deficient mice conducted so far could not clarify the role of 
this catalytic subunit in hypertension. For example, the published results 
describing the effect of Nox2 on the basal blood pressure are contradictory 
(Wang et al., 2001; Touyz et al., 2005). In addition, a role for Nox2 in 
mediating angiotensin II-induced hypertension could not be demonstrated 
under acute as well as chronic conditions.  Deletion of Nox2 prevented 
vascular hypertrophy after acutely elevated angiotensin II levels (6 days 
infusion) (Wang et al., 2001), but not under chronic settings of angiotensin II 
upregulation (TTRhRen transgenic/Nox2 deficient mice) (Touyz et al., 2005).  
The role of Nox1 in angiotensin II-mediated hypertension is highlighted in 
three recent publications. Dikalova and colleagues showed that in transgenic 
mice, which overexpress Nox1 in smooth muscle cells, oxidative, pressor and 
hypertrophic responses to angiotensin II were increased (Dikalova et al., 
2005). Matsuno et al. (2005) reported decreased pressor responses to 
angiotensin II infusion in Nox1-deficient mice due to increased NO 
bioavailability. In line with this, the endothelium-dependent relaxation was 
preserved in aortae of knockout mice infused with angiotensin II (Matsuno et 
al., 2005). Furthermore, there was no change in the basal blood pressure. In 
contrast to that, Gavazzi and colleagues found that the basal blood pressure 
was moderately decreased in a different line of Nox1-deficient mice (Gavazzi 
et al., 2006). Gavazzi et al. (2006) reported further, that the sustained blood 





and that aortic media hypertrophy was significantly reduced due to a decrease 
in extracellular matrix accumulation in comparison to sham treated wild-type 
mice. In contrast, Matsuno and colleagues did not find any differences in 
aortic hypertrophy in knockout and wildtype mice that were infused with 
angiotensin II. The discrepancy between the two studies was explained by the 
use of animals of different ages and different angiotensin II doses (3 
mg/kg/day Gavazzi et al., 0.7 mg/kg/day Matsuno et al.). However, all these 
studies point to the involvement of Nox1 in endothelial dysfunction and 
hypertension and are in agreement with a pathological role of increased Nox1 
expression in aged SHR observed in the present study. Based on this, it can 
be proposed that Nox1-derived superoxide scavenges NO and leads to 
endothelial dysfunction in this model of genetic hypertension. Taking into 
account the findings of Gavazzi et al. (2006), it can be further assumed that 
Nox1 is involved in the increased ECM accumulation observed in SHR aortae. 
In this context, it should be mentioned that ROS have more pathogenic effects 
than only scavenging NO, e.g. direct regulation of matrix metalloproteinases 
(Rajagopalan et al., 1996) and VSMC proliferation, processes that are 
involved in the remodeling of vessels (Taniyama & Griendling, 2003). 
Nevertheless, the correlation between Nox1 overexpression and ECM 
accumulation in SHR remains hypothetically and the observed vascular 
remodeling should rather be considered a multifactorial consequence of the 
chronic hypertension in these animals.  
In contrast to Nox1 and Nox2 protein levels, Nox4 levels were not significantly 
changed in SHR. Thus, it is tempting to suggest a physiological role for Nox4 
in maintaining steady-state levels of ROS. Such a basic function of Nox4 is 
also supported by the fact that this isoform is highly expressed in endothelial 
cells (Ago et al., 2004) and VSMC (Wingler et al., 2001). Its activation seems 
to be independent of cytosolic subunits, in particular p47phox (Martyn et al., 
2006), and may therefore not be inhibitable by apocynin. Unlike Nox4, Nox1 
and Nox2 preferably mediate stress responses under pathophysiological 
conditions and therefore represent promising targets for the treatment of 
vascular diseases. Indeed, a putative therapeutic relevance of targeting Nox1 





antioxidative effect of atorvastatin to decreased mRNA expression levels of 
Nox1 and p22phox in SHR treated with this compound (Wassmann et al., 
2002). In contrast to the clearer role of Nox1, the function of increased Nox2 
expression remains to be elucidated. 
 
Interestingly, in addition to the expected Nox1 protein band of approximately 
60 kD another two bands at the size of 126 kD and 138 kD were observed. 
These were not detectable when the Nox1 antibody was preincubated with 
the immunizing peptide suggesting their specificity for Nox1. Since Nox2 was 
shown to be highly glycosylated, it was tested whether these high molecular 
weight bands result from a glycosylation of Nox1, but deglycosylation 
experiments with PNGase F have failed. Another hypothesis could be that the 
high molecular weight bands resulted from complexes of Nox1, either with 
itself (homodimers) or possibly with other proteins. Assuming that these high 
molecular weight bands are really complexes of Nox1, the bonds have to be 
very strong since neither mercaptoethanol, SDS nor heating were able to 
cleave them. Such Nox1 derivatives could be storage forms that could also 
explain why changes in Nox1 expression were observed on a protein but not 
on a mRNA level. However, further studies have to be carried out to reveal 
the exact identity and function of these Nox1 positive bands. Current 
investigations employ low-temperature SDS-PAGE to test whether the 
stability/formation of the high molecular Nox1 variants is temperature-




6.4 Localization of Nox isoforms in the aortic wall 
 
NADPH oxidase activity has been detected in all layers of the vasculature. 
Concomitant, p22phox, which has been described to colocalize with Nox1, 
Nox2 and Nox4, was found in all vascular cells (Brandes & Kreuzer, 2005). 
However, the distribution of the Nox isoforms is poorly investigated at the 





in SHR and WKY aortae using Nox1, Nox2 and Nox4 antibodies. The 
distribution of Nox isoforms in SHR and WKY was compared and the 
colocalization of the relevant isoform, Nox1, with specific EC and VSMC 
markers as well as the signal arising from ROS-mediated DHE fluorescence 
was studied. 
Nox1 was mainly expressed in the media of the aortic wall where it 
colocalized with α-SM-actin verifying that it is expressed in VSMC. This is in 
line with several studies showing Nox1 mRNA and protein in isolated rat as 
well as human VSMC (Lassegue & Clempus, 2003; Hanna et al., 2004). In a 
recent immunohistochemical study, Nox1 was detected in the aortic media of 
5 week old Sprague-Dawley rats confirming this observation (Ago et al., 
2005). In a previous publication, Ago et al. (2004) were not able to detect 
Nox1 in aortic endothelial cells of Sprague Dawley rats. Interestingly, while no 
or at least very little Nox1 protein was detected in the intima of normotensive 
WKY in the present study, the Nox1 signal was very strong in the intima of 
SHR aortae. Colocalization of the Nox1 signal with the endothelial cell marker, 
RECA-1, demonstrated a SHR-specific expression in EC. Nox1 
immunoreactivity was also found in the adventitia of SHR aortae, while it 
appeared to be absent in the adventitial layer of WKY. However, these 
adventitial Nox1 fluorescence signal was rather weak and merged with the 
nuclear staining; therefore the results require cautious interpretation. 
Altogether it seems that chronic hypertension, as observed in aged SHR, is 
accompanied by an enhanced Nox1 expression in the media and especially in 
the intima, while the normotensive WKY controls mainly express Nox1 in the 
aortic media. 
The link between enhanced Nox1 immunofluorescence and increased ROS 
production was investigated by combining immunohistochemistry of Nox1 with 
in situ detection of ROS using DHE. Nox1 signals matched well with the ROS 
formation in the media and in the intima of SHR aortae pointing to a significant 
role of this Nox isoform in oxidative stress and endothelial dysfunction in 
these animals. 
Nox2 was detected in the adventitia and the intima and seemed to be absent 





EC (Gorlach et al., 2000) and fibroblasts (Rey & Pagano, 2002), but not in 
VSMC of conduit vessels (Lassegue & Clempus, 2003). In the present study, 
only a slight difference in Nox2 expression between SHR and WKY aortae 
was detected immunohistochemically. In this context it should be mentioned 
that results of DHE measurements combined with Nox1 immunofluorescence 
showed areas in the intima and the adventitia of SHR that did not match, 
while the NADPH oxidase inhibitor VAS2870 suppressed the ROS formation 
in all layers of the aortic wall. Therefore it can be suggested that the 
remaining ROS formation that did not colocalize with Nox1 was produced 
from Nox2-containing NADPH oxidases. This is supported by the upregulation 
of Nox2 protein in aortic homogenates of SHR in comparison to their WKY 
controls. 
Nox4 protein was found throughout the vessel wall, with a strong signal in the 
adventitia and in the media, but also some expression in the intima of SHR 
and WKY aortae. In line with these findings, Nox4 was described to be 
abundantly expressed in all vascular cells (Brandes & Kreuzer, 2005). Nox4 
colocalized with α-SM-actin indicating its expression in VSMC. In mice aortic 
smooth muscle cells, it was shown that the NADPH oxidase activity largely 
depended on Nox4 under resting conditions, and proatherogenic stimuli such 
as IL-β, thrombin and PDGF decreased activity and expression of Nox4 
(Ellmark et al., 2005). In rat and human EC, Nox4 was considered to be the 
major catalytic NADPH oxidase component (Ago et al., 2004). In the present 
study, the most intensive signals of Nox4 were found in the adventitia of SHR 
and WKY aortae, while the expression in the EC layer appeared to be 
comparatively weak. However, quantitative statements concluded from 
immunohistochemistry have to be cautiously interpreted and should be 
confirmed by Western blot analysis in future studies. In summary, the 
abundant expression, which was found in SHR as well as WKY rats, together 
with the constitutive, stimuli- and subunit-independent activity of Nox4-based 
NADPH oxidases is suggestive of a physiological role of Nox4 in homeostasis 







6.5 Role of eNOS in aortic endothelial dysfunction of aged SHR 
 
Decreased NO bioavailability is the hallmark of endothelial dysfunction (Cai & 
Harrison, 2000). It can be a result of either increased scavenging or 
decreased production of NO (Forstermann, 2006). This study could 
demonstrate that increased scavenging via NADPH oxidase-derived ROS is a 
principal cause for endothelial dysfunction in SHR aortae. Furthermore, to 
investigate whether the expression of eNOS, the NO producing enzyme, is 
altered, protein expression analysis was perfomed in SHR and WKY aortae. 
However, no significant differences in protein expression were observed 
between SHR and normotensive WKY rats; quite to the contrary, eNOS 
protein expression appeared to be increased. Thus the hypothesis that a 
decrease in the expression of eNOS contributes to endothelial dysfunction 
could not be confirmed. This is in line with several other investigations which 
showed that cardiovascular diseases are associated with an increase in 
eNOS expression (Vaziri et al., 1998; Hink et al., 2001; Guzik et al., 2002). 
Likewise in young (Vaziri et al., 1998) and 7 month old SHR rats (Ulker et al., 
2003), eNOS expression was found to be significantly upregulated. The 
increased eNOS expression could serve as an initial compensatory response 
to hypertension. Since the observed differences in the expression level were 
only marginal between aged SHR and WKY rats this compensatory effect 
may be eliminated with age. However, the protein levels of eNOS may also 
not reflect the activity of the enzyme. Thus eNOS activity in the aortae should 
be measured in follow up studies. 
Another mechanism contributing to endothelial dysfunction is the “uncoupling” 
of the eNOS enzyme. “Uncoupled” eNOS produces superoxide instead of NO 
due to a deficiency of its substrate L-arginine, its co-factor BH4 and/or 
oxidation of the zinc thiolate cluster of the enzyme (Forstermann, 2006). Since 
L-NAME did not have any effect on the ROS levels detected with the DHE 
assay, eNOS “uncoupling” does not seem to be involved in oxidative stress 
and endothelial dysfunction found in SHR aortae. Some studies have shown 
that oxidative stress and endothelial dysfunction can be reversed by 





models (Pieper, 1997; Shinozaki et al., 2000). However, it is difficult to confirm 
the role of eNOS uncoupling from these studies. On the one hand, BH4 is a 
strong antioxidant (Forstermann, 2006) and can therefore combat oxidative 
stress and improve the endothelial function due to unspecific ROS scavenging 
effects. On the other hand, if BH4 specifically targets eNOS, this would result 
in an increased NO production, which then is in competition with all ROS 
irrespective of their source of production.  
In summary, the data obtained in this study suggest that eNOS does not play 
a significant role in the oxidative stress and endothelial dysfunction observed 
in SHR aortae.  
 
 
6.6 VAS2870, a novel compound in the pharmacology of NADPH 
oxidases 
 
Although it is generally agreed that NADPH oxidases are an important 
component responsible for the generation of oxidative stress in numerous 
diseases, the pharmacology of NADPH oxidases is poorly developed. The 
compounds used so far to target this enzyme complex are either non-specific 
and/or mechanistically not well understood. For example, the frequently used 
substance, DPI, is an inhibitor of all flavoenzymes and thereby potentially 
inhibits other ROS sources like xanthine oxidase or uncoupled eNOS. 
Therefore, the application of DPI is limited to in vitro assays, where the DPI-
inhibitable ROS generation can be specified by the additional use of specific 
inhibitors of the other flavoenzymes like oxypurinol and L-NAME, respectively. 
Apocynin, which has also been used in this study, is most frequently applied 
as a specific inhibitor of NADPH oxidases. The proposed mechanism of action 
of this vanilloid substance is the prevention of p47phox translocation to the 
membranic NADPH oxidase subunits. Apocynin is not toxic and possesses a 
good oral bioavailability and was therefore described as a promising 
candidate for in vivo research and therapeutic applications. However, the use 
of this compound in the pharmacological research of NADPH oxidases is 





that apocynin increases ROS production in fibroblasts and neuronal cells 
instead of decreasing it (Riganti et al., 2005; Vejrazka et al., 2005). According 
to its proposed mechanism of action, apocynin targets the p47phox-based 
NADPH oxidases only and therefore should not interfere with NADPH 
oxidases that are independent of p47phox like Nox4. However, this could also 
be a positive aspect, if solely p47phox-based NADPH oxidases are involved in 
the pathology. Moreover, apocynin has to be activated by peroxidases, which 
probably does not occur in all types of tissues. Furthermore, studies in our lab 
showed that apocynin interferes with several ROS detection dyes and/or 
possesses unspecific antioxidant properties. Although this substance was 
effective in the present study and even in several in vivo studies, results 
obtained with apocynin should always be interpretated with caution due to the 
reasons described above. 
In the present study, the novel NADPH oxidase inhibitor VAS2870 (Tegtmeier 
F et al., 2005) was investigated and characterized. The compound was 
effective in suppressing oxidative stress and improving endothelial 
dysfunction of aged SHR rats. This is the first study showing that VAS2870 is 
effective in diseased tissue. Very recently Ten Freyhaus et al. (2006) reported 
that VAS2870 inhibited PDGF-induced NADPH oxidase activity, ROS 
formation and migration of VSMC that were isolated from the aorta of 6-10 
week old WKY rats. In another study, VAS2870 was effective in preventing 
the oxidized low-density lipoprotein (oxLDL)-mediated ROS formation in 
primary human umbilical vein EC (HUVEC) (Stielow et al., 2006). Both studies 
showed the efficiency of VAS2870 in suppressing NADPH oxidase activity in 
vascular cells while not being toxic at least in the concentrations investigated. 
While the PDGF-mediated ROS formation in VSMC appears to depend mainly 
on Nox1 expression (Lassegue et al., 2001; Pleskova et al., 2006), Nox4 is 
the major isoform in HUVEC (Ago et al., 2004) and was therefore related to 
the oxLDL-mediated ROS formation (Stielow et al., 2006). Since VAS2870 
also inhibited the Nox2-mediated oxidative burst in HL60 cells (Tegtmeier F et 
al., 2005) and in a cell-free system of human neutrophils (Ten Freyhaus et al., 
2006), it is concluded that VAS2870 is not selective for any Nox isoforms. 





suppressed ROS formation throughout the whole vessel wall of SHR. While 
Nox1 was shown to colocalize with the ROS formation in the media and partly 
the intima of SHR aorta, distinct VAS2870 inhibitable ROS formation was 
found in the adventitia and intima indicating that its sources are Nox2 and/or 
Nox4.   
Own investigations in which the NADPH oxidase inhibitors apocynin, AEBSF 
and DPI were compared with VAS3947 (3-benzyl-7-(2-oxazolyl)thio-1,2,3-
triazolo[4,5-d]pyrimidine), a derivative of VAS2870, are in line with such a 
hypothesis. In this study, VAS3947 suppressed NADPH oxidase activity in 
different cell lines that predominantly express either Nox1, Nox2 or Nox4 with 
IC50 values in the low µM range. Furthermore, it was shown that VAS3947 
has no antioxidative potential and is not a flavoenzyme inhibitor like DPI. The 
high potency of the VAS compounds is also confirmed in the present study 
where a concentration of 10 µM VAS2870 was equally effective as 100 µM 
and 1 mM apocynin, respectively. These high concentrations of apocynin, 
which are needed to successfully suppress NADPH oxidases, are a further 
disadvantage of this compound, because the likelihood of unspecific actions 
increases with concentration. The high potency and apparently high specificity 
of VAS2870 for NADPH oxidases makes this inhibitor to a very powerful tool 
in experimental pharmacology. With regard to the therapeutic potential of 
VAS2870 the unselectivity for the Nox isoforms could be a disadvantage in 
the treatment of oxidative stress, since inhibition of Nox2 should result in 
impaired immune function and inhibition of Nox4 which is proposed in cell 
signaling could potentially lead to the interruption of important physiological 
pathways. However, the unselectivity could be also an advantage, since 
several Nox isoforms seem to be involved in vascular pathology including 
Nox2. Therefore, a modulation rather then a full inhibition of these enzymes 
and/or a local delivery (e.g. via stents) of the inhibitors should circumvent 
possible immune-suppressing effects. Moreover, statins which should also 
inhibit Nox2-based NADPH oxidases were not found to possess side effects 






Future studies should elucidate the mechanism of action of VAS2870, which 
appears to be different from most of the other NADPH oxidase inhibitors. 
While substances like apocynin, AEBSF or gp91phox were shown to target the 
assembly of NADPH oxidase subunits (Stolk et al., 1994; Diatchuk et al., 
1997; Rey et al., 2001), it was shown that VAS2870 does not affect PMA 
stimulated p47phox translocation in human PMNs (Ten Freyhaus et al., 2006). 
In line with this is the observation that VAS2870 and VAS3947 inhibit NADPH 
oxidase activity in cells that predominantly express Nox4, since Nox4 was 
shown to be active independently of p47phox and p67phox (Shiose et al., 2001; 
Ago et al., 2004). Therefore, it seems likely that VAS2870 directly interacts 
with the catalytic Nox proteins. As a 1,2,3-triazolo[4,5-d]pyrimidine, VAS2870 
appears to be structurally related to purines such as guanosine and even 
more closely to adenosine. Considering this analogy, the NADPH or the FAD 
binding sides of the Nox proteins appear to be reasonable target points for 
VAS2870. However, due to the analogy to purines one has to consider that 
this compound potentially modulates other targets in addition to NADPH 
oxidases implying supplementary effects in a physiological system. Indeed, 7-
amino-derivatives of 1,2,3-triazolo[4,5-d]pyrimidines were already described 
to possess affinity to A1 and A2A adenosine receptors (Betti et al., 1998). 
Additionally, purinoreceptors such as P2X appear to be a potential target, 
since they are also involved in vascular tone (Judkins et al., 2006) and 
inhibitors of these receptors were found to inhibit vascular NADPH oxidases 
(Drummond 2006, unpublished observations). Hence, an interaction of 
VAS2870 with adenosine and purine receptors should be investigated in 
future studies.  
 
 
6.7 Targeting ROS as a treatment of cardiovascular diseases 
 
Many experimental studies suggest that oxidative stress is involved in the 
pathophysiology of cardiovascular diseases. Animal studies, for the most part, 
support the fundamental role of ROS in diseases such as atherosclerosis, 





hypercholesterolemia, hyperhomocysteinemia, diabetes mellitus or 
renovascular hypertension exhibit increased ROS generation as suggested 
amongst others by elevated F2 isoprostane levels (for a review see Griendling 
& FitzGerald (2003)). Therefore, recent therapeutic approaches have been 
aimed at combating oxidative stress with antioxidants such as Vitamin E and 
C. On the whole, clinical trials with antioxidants have been disappointing. For 
example, the Heart Outcomes Prevention Evaluation (HOPE) study, the 
Medical Research Council/ British Heart Foundation (MRC/BHF) heart 
protection study and several other clinical trials failed to demonstrate 
significant benefits of vitamin E or C supplementation on cardiovascular 
endpoints. However, from the twelve prospective antioxidant clinical trials 
published so far, five studies such as the Antioxidant Supplementation in 
Atherosclerosis Prevention (ASAP) study could demonstrate a positive effect 
of antioxidant supplementation (for a review, see Jialal and Devaraj (2003) 
and  Singh & Jialal (2006)). Still, overall results of clinical trials are rather 
sobering in consideration of the promising experimental data. Potential 
reasons for the failure of these studies have been frequently discussed and 
centered around inappropriate study designs and investigated patient 
populations as well as the antioxidants used (Jialal & Devaraj, 2003; Touyz, 
2004). Indeed, the most widely examined antioxidants in trials, vitamins E and 
C, may also have prooxidant properties (Podmore et al., 1998; Abudu et al., 
2004). Furthermore, these vitamins mainly react with superoxide by 
abstracting an electron and converting it into H2O2, thereby leaving HOCl 
unaffected and even increasing H2O2 production (Touyz, 2004). It cannot be 
ruled out that these ROS are more important in mediating vascular damage 
than superoxide itself. For these reasons, direct inhibition of the ROS sources 
should be more efficacious in ameliorating oxidative stress than scavenging 
ROS when they are already present. NADPH oxidases have been identified 
as the main source of oxidative stress in the present as well as in other 
studies. Thus, modulating these enzymes with inhibitors such as the novel 
compound, VAS2870, promises to be more successful in treating diseases 







6.8 Future perspectives 
 
The present study provides strong evidence that NADPH oxidases are the 
major source of oxidative stress and associated endothelial dysfunction in a 
rat model of progressed genetic hypertension. The catalytic subunit Nox1 
appears to possess a predominant role in the NADPH oxidase-mediated 
oxidative stress. However, an upregulation of Nox1 was only found on the 
protein level and – in addition to the expected protein band – two high 
molecular weight variants were detected in the Western blots. Future studies 
are necessary to elucidate the constitution, formation and relevance of these 
Nox1 immunoreactive bands. Immunoprecipitation followed by MALDI-TOF 
analysis as well as low temperature SDS-PAGE should contribute to a more 
detailed understanding towards the significance of these bands. 
VAS2870 was shown to effectively inhibit NADPH oxidase-mediated oxidative 
stress and thereby to significantly improve endothelial dysfunction in SHR 
aortae. Considering the need of specific inhibitors of NADPH oxidases and 
the role of the enzymes in far more diseases than hypertension, VAS2870 
may be an interesting model compound for the treatment of diseases 
associated with oxidative stress and deserves further investigations. Future 
studies should investigate the mechanism of action, its specifity for NADPH 
oxidases and whether any possible selectivity for one of the Nox isoforms 
exists. Activity studies in Nox isoform-overexpressing cells could address 
such demands. Furthermore, future investigations have to determine the in 






Vascular oxidative stress is associated with a dysfunction of endothelium-
dependent relaxation. Inactivation of nitric oxide by superoxide and other 
reactive oxygen species (ROS) appears to occur under conditions such as 
diabetes mellitus, hypercholesterolemia or arterial hypertension. NADPH 
oxidases have been identified as major source of ROS in blood vessels. The 
present study investigates the role of NADPH oxidases in aortae of 12-14 
month old spontaneously hypertensive rats (SHR) in comparison to age-
matched Wistar Kyoto rats (WKY). 
ROS production was largely increased in aortae of SHR as measured by in 
situ detection of DHE fluorescence. Suppression of ROS formation by the 
NADPH oxidase inhibitors, apocynin and the novel compound VAS2870, but 
not by the eNOS inhibitor L-NAME or the xanthine oxidase inhibitor 
oxypurinol, suggested NADPH oxidases as a major source of oxidative stress. 
In line with these findings, NADPH oxidase activity in aortic homogenates of 
SHR was significantly elevated. 
NADPH oxidases are multimeric complexes consisting of several cytosolic 
and two membranic subunits, namely p22phox and a catalytic Nox isoform. In 
rat aortae, the isoforms Nox1, Nox2 and Nox4 are expressed, which was 
confirmed by RT-PCR in aortic homogenates of SHR and WKY. 
Immunohistochemical analysis of the vessels demonstrated a predominant 
location of Nox1 in the aortic media. Nox2 was localized in the adventitia as 
well as the intima and Nox4 was located throughout the aortic wall. 
Quantitative Western blot analysis revealed increased levels of Nox1 and 
Nox2 protein in SHR aortic homogenates, while Nox4 expression was not 
significantly changed. Furthermore, Nox1 protein appeared to be upregulated 
especially in the intima of SHR aortae as indicated by colocalization of Nox1 
immunofluorescence with the VSMC marker α-SM-actin and the endothelial 
cell marker RECA-1. These data suggest that Nox1 and Nox2-based NADPH 






Acetylcholine-induced endothelial-dependent relaxation was determined to 
investigate whether the NADPH oxidase-produced oxidative stress is linked to 
endothelial dysfunction. Vasorelaxation was impaired in aortic rings of SHR in 
comparison to the WKY controls. However, it was significantly improved in the 
presence of apocynin and VAS2870 in SHR and to a smaller extent in WKY, 
indicating the functional relevance of the enhanced NADPH oxidase activity. 
In conclusion, Nox1 and Nox2 comprising NADPH oxidases were identified as 
major sources of oxidative stress in SHR aortae and thus contributed 
significantly to endothelial dysfunction. Targeting these enzymes therefore 
promises to be of immense therapeutic relevance. The novel NADPH oxidase 
inhibitor VAS2870 was shown to effectively suppress the oxidative stress and 
to improve the endothelial function in SHR. In consequence, the present study 
highlights VAS2870 as an experimental tool in the pharmacology of NADPH 
oxidases and – furthermore - as an interesting model compound for the 







Vaskulärer oxidativer Stress führt zu einer Beeinträchtigung der 
endothelabhängigen Gefäßrelaxation. Stickstoffmonoxid scheint unter 
Bedingungen, wie sie bei Diabetes mellitus, Hypercholesterolämie oder 
arteriellem Bluthochdruck vorliegen, von Superoxid und anderen reaktiven 
Sauerstoffspezies (ROS) inaktiviert zu werden. Als Hauptquellen für ROS in 
Blutgefässen sind NADPH Oxidasen identifiziert worden. Die vorliegende 
Arbeit untersucht die Rolle von NADPH Oxidasen in Aorten von 12 bis 14 
Monate alten spontan-hypertensiven Ratten (SHR) im Vergleich zu 
gleichaltrigen Wistar Kyoto Ratten (WKY). 
Die in-situ Detektion von ROS mittels DHE Fluoreszenz zeigte, dass die ROS 
Produktion in Aorten von SHR stark erhöht ist. Die NADPH Oxidase-
Inhibitoren Apocynin und die neue Substanz VAS2870, nicht aber der eNOS-
Hemmstoff L-NAME oder der Xanthinoxidase-Inhibitor Oxypurinol 
unterdrücken diese ROS Bildung, was auf NADPH Oxidasen als Hauptquelle 
für oxidativen Stress hinweist. Mit diesem Befund einhergehend zeigten SHR 
Aorten eine erhöhte NADPH Oxidase Aktivität. 
NADPH Oxidasen sind Multimer-Komplexe, die aus verschiedenen 
zytosolischen und zwei membranständigen Untereinheiten, p22phox und einer 
katalytischen Nox Isoform, bestehen. In Rattenaorten sind die Isoformen 
Nox1, Nox2 und Nox4 exprimiert, wie mittels RT-PCR in Aortenhomogenaten 
von SHR und WKY bestätigt wurde. Die immunhistochemische Analyse der 
Gefässe deutete eine primäre Lokalisation von Nox1 in der Media an, 
während Nox2 in Adventitia und Intima und Nox4 in der gesamten 
Aortenwand gefunden wurden. Im Vergleich zu WKY, konnten erhöhte Nox1 
und Nox2 Proteinspiegel im SHR-Aortenhomogenat mittels quantitativer 
Western Blot Analyse nachgewiesen werden, während die Nox4 Expression 
nicht signifikant verändert war. Weiterhin war die Nox1 Expression im 
Endothel der SHR Aorten hochreguliert, wie Kolokalisierungsexperimente von 
Nox1 mit dem glatten Muskelzell-Marker α-SM-actin und dem Endothelzell-





darauf hin, dass Nox1 und Nox2-basierte NADPH Oxidasen den oxidativen 
Stress in der Aortenwand gealteter SHR verursachen. 
Um zu untersuchen, ob der durch NADPH Oxidasen hervorgerufene oxidative 
Stress mit einer endothelialen Dysfunktion der Aorten zusammenhängt, wurde 
die Azetylcholin-induzierte, endothelabhängige Gefässdilatation bestimmt. In 
SHR-Aorten war die Relaxation im Vergleich zur WKY Kontrolle 
beeinträchtigt, konnte aber in Anwesenheit von Apocynin und VAS2870 
signifikant verbessert werden. Diese, durch die Inhibitoren bewirkte 
Verbesserung der Relaxation war in WKY Aorten weniger ausgeprägt, was 
auf die funktionelle Relevanz der erhöhten NADPH Oxidase Aktivität 
hindeutet. 
Daraus lassen sich folgende Schlussfolgerungen ableiten: Nox1 und Nox2- 
basierte NADPH Oxidasen wurden als Hauptquellen für oxidativen Stress in 
SHR Aorten identifiziert und tragen damit signifikant zur endothelialen 
Dysfunktion bei. Deshalb stellt die Hemmung dieser Enzyme einen 
vielversprechenden, therapeutischem Ansatz dar. Der neuartige NADPH 
Oxidase Hemmstoff VAS2870 konnte den oxidativen Stress in SHR Aorten 
wirksam reduzieren und damit deren endotheliale Funktion verbessern. Somit 
verdeutlicht die vorliegende Arbeit das Potential von VAS2870 als 
experimentelles „Tool“ in der Pharmakologie von NADPH Oxidasen. 
Darüberhinaus stellt VAS2870 auch eine interessante Modellsubstanz für die 
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